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1. ABSTRACT (English) 
 
Activating mutations in the juxtamembrane domain (FLT3-length mutations, FLT3-LM) 
and in the protein tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD) represent the 
most frequent genetic alterations in acute myeloid leukemia and define a distinct 
molecular entity in AML.  
 
In this work two new mutations in FLT3 gene are described: the first is a 6-bp 
insertion on the activation loop of FLT3 between codons 840 and 841 of FLT3 (FLT3-
840GS) in two unrelated patients with AML and the second is a single and identical 
T→C nucleotide exchange in both the MM6 and MM1 cell lines resulting in a V592A 
mutation. 
In functional analyses we could show that these mutants are hyperphosphorylated on 
tyrosine and confer interleukin-3 independent growth to Ba/F3 cells, which can be 
inhibited by a specific FLT3 PTK inhibitor. 
 
These results show for the first time that in addition to known mutations in the JM and 
the catalytic domain, further activating mutations exist in the FLT3 gene. 
  
Furthermore we could show that distinct activating FLT3-TKD mutations at position 
D835 mediate primary resistance to FLT3 PTK inhibitors in FLT3 transformed cell 
lines. In the presence of increasing concentrations of the FLT3 PTK inhibitor SU5614 
inhibitor resistant Ba/F3 FLT3-internal tandem duplication (ITD) cell lines (Ba/F3 
FLT3-ITD-R1-4) were generated and characterized by a 7-26 fold higher IC50 to 
SU5614 compared to the parental ITD cells. The detailed molecular characterization 
of ITD-R1-4 cells demonstrated that specific TKD mutations (D835N and Y842H) on 
the ITD background were acquired during selection with SU5614. Introduction of 
these “duale” ITD-TKD, but not single D835N or Y842H FLT3 mutants in Ba/F3 cells 
restored the FLT3 -inhibitor resistant phenotype. 
 
These data show that pre-existing or acquired mutations in the PTK domain of FLT3 
can induce drug resistance to FLT3 PTK inhibitors in vitro. These findings provide a 
molecular basis for the evaluation of clinical resistance to FLT3 PTK inhibitors in 
patients with AML.  
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2. ZUSAMMENFASSUNG 
 
Aktivierende Mutationen in der juxtamembranösen Region (FLT3-Längenmutationen, 
FLT3-LM; FLT3- Interne Tandemduplikation, FLT3-ITD) und der Tyrosinkinase-
Domäne (FLT3-TKD, FLT3-D835) von FLT3 stellen die häufigsten genetischen 
Alterationen in der AML dar und definieren eine klinisch-prognostische-Subgruppe in 
der AML. 
 
In der vorliegenden Arbeit wurden zwei neue Mutationen in FLT3 identifiziert und 
charakterisiert. Die erste Mutation (FLT3-840GS) wurde in zwei Patientenproben 
nachgewiesen. Moleculargenetisch stellte diese eine Längenmutation in Exon 20 dar, 
und war durch eine 6 bp-grosse  Insertion bzw. Glycin+Serin Insertion in der 
Aktivierungsschleife der katalytischen Domäne zwischen den Kodons 840 und 841 
nahe der Aktivierungsschleife verursacht. Die zweite Mutation, eine aktivierende 
Punktmutation in der JM-Region von FLT3 (FLT3-V592A) wurde in den AML-Zelllinien 
MonoMac 6 und MonoMac 1 identifiziert. Die funktionelle Analyse ergab, dass diese 
Mutanten eine konstitutive Tyrosinphosphorylierung  aufweisen und zu einem IL-3 
unabhängigem Wachstum in Ba/F3 Zellen führen, welches durch einen spezifischen 
Proteintyrosinekinase (PTK) Inhibitor gehemmt werden konnte.  
Diese Ergebnisse zeigen, dass neben den bisher beschriebenen noch weitere 
aktivierende Mutationen in der JM- und der katalytischen Domäne in FLT3 Gen 
existieren. 
 
Die weiteren Untersuchungen zeigten, dass verschiedene FLT3-TKD (D835) 
Mutationen eine deutlich unterschiedliche Empfindlichkeit gegenüber selektiven FLT3 
PTK Inhibitoren aufwiesen. Weiter wurde gezeigt, dass durch kontinuierliche 
Exposition von FLT3-ITD transformierten Leukämiezellen mit dem FLT3 PTK Inhibitor 
SU5614 in vitro resistente Mutanten generiert werden können. Die molekulare und 
funktionelle Charakterisierung dieser SU5614-resistenten Zelllinien (Ba/F3 FLT3-ITD-
R1-4) ergab, dass spezifische Mutationen in der TKD-Domäne ursächlich für die 
Inhibitorresistenz verantwortlich waren.  Die FLT3-ITD-R1-4 Zellen wiesen somit 
Doppelmutationen im FLT3-Gen (LM + TKD) auf und waren durch eine 7-26-fach 
höhere IC50 gegenüber dem Inhibitor gekennzeichnet. Solche Doppelmutanten von 
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FLT3 wurden mittels in- vitro- Mutagenese generiert und rekapitulieren in Ba/F3 
Zellen den SU5614-resistenten Phänotyp. 
  
Diese Ergebnisse zeigen, dass prä-existierende oder erworbene FLT3-TKD 
Mutationen Resistenzen gegenüber FLT3-PTK Inhibitoren in vitro induzieren können. 
Diese Befunde stellen die molekulare Basis für zelluläre Resistenzen gegenüber 
FLT3-PTK Inhibitoren bei Patienten mit AML dar.  
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3. INTRODUCTION 
Acute myeloid leukemia (AML) is the most common form of acute leukemia 
occurring in adults, comprising approximately 80 to 85% of cases of acute 
leukemia diagnosed in individuals greater than 20 years of age. Currently, more 
than 80% of young adults and 60% of all patients can achieve complete 
remissions.  
Due to the identification of leukemic fusion genes encoded by balanced 
chromosomal translocations, the pathophysiology of certain AML subtypes has 
been identified. Prognostic factors and disease heterogeneity can be defined using 
molecular markers and provide the potential for individualizing of antileukemic 
therapy in patients with AML. 
 
 
3.1 Acute myeloid leukemia (AML) 
 
The pathophisiology of AML can be explained by acquired genetic changes in 
bone marrow stem cells that cause a complete or partial block in normal 
hematopoietic stem cell maturation. The genetic changes may involve mutations 
that lead to activation of growth-promoting proto-oncogenes, inactivation of tumor 
suppressor genes, or alterations of transcription factors. 
 
Although the acquired genetic lesions that lead to leukemia are being rapidly 
defined, the causative agent or environmental factor can be identified for a small 
fraction of patients with AML. Nonetheless, leukemias clearly occur with increased 
frequency after military or therapeutic radiation exposure, after certain types of 
chemotherapy and with heavy and continuous occupational exposure to benzene.  
 
There have been a number of large, survey-type epidemiologic studies that have 
attempted to link a variety of environmental exposures to leukaemia incidence. 
But, as in many epidemiologic studies, it is difficult to quantify the degree of 
exposure to various environmental insults. There may be a small increased risk 
associated with cigarette smoking, whereas exposure to electromagnetic radiation 
seems an unlikely cause of AML. However, occupational exposures, particularly to 
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benzene or petrochemicals have been implicated in the development of AML. 
Alkylating agents used in Hodgkin’s disease, multiple myeloma, ovarian cancer, 
and colon cancer have been associated with loss of chromosome 5 and 7, 
whereas tenoposide use in childhood acute lymphoblastic leukaemia (ALL) and 
high-dose anthracycline/cyclophosphamide combinations have caused alterations 
of chromosome 11q23. With the few exceptions noted above, however, there is no 
clear relationship between environmental exposures and the occurrence of acute 
leukemia. 
 
 
 
3.1.1 Classification of AML 
In 1976, a group of morphologists from France, the United States, and Great 
Britain (FAB) suggested a classification system designed to define distinct 
subtypes of AML and ALL (M0-M7) (Table 1).  
 
 
 
Table 1: FAB classification of AML. 
Tdt-terminal deoxinucleotide transferase, HLA-DR-human leukocyte antigen D-related 
(from ‘’Cancer Medicine’’) 
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The diagnosis of AML requires that myeloblasts constitute 20% (based on a recent 
World Health Organization classification system) or more of bone marrow cells or 
circulating white blood cells. Neoplastic promyelocytes, monoblasts, or 
promonocytes and megakaryoblasts are included in this calculation and their 
presence defines the various subtypes of AML. Monoclonal antibodies directed 
against antigen groups termed cluster designation (CD) considered to be restricted 
to cells committed to myeloid differentiation are also helpful. Antibodies against 
CD11b, CD13, CD14 and CD33 are used most commonly.  
The new WHO classification retains the morphologic subgroups of the FAB 
system, but has created new categories which recognize the importance of certain 
cytogenetic translocations as predictors of response to therapy (Table 2). 
 
    
 
 
Table 2: WHO classification of AML (from ‘‘Cancer Medicine’’) 
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3.2 Receptor tyrosine kinases 
 
3.2.1 Signaling through receptor tyrosine kinases 
The extracellular signal proteins that act through receptor tyrosine kinases consist 
of a large variety of secreted growth factors and hormones. The human genome 
as currently sequenced, is thought to contain 90 tyrosine kinase genes, of which 
58 are of the receptor type. Receptor tyrosine kinases can be classified into more 
than 16 structural families, each dedicated to its complementary family of protein 
ligands.  
 
In all cases, the binding of the signal protein to the ligand-binding domain on the 
outside of the cell activates the intracellular tyrosine kinase domain (Figure 1). 
Once activated, the kinase domain transfers a phosphate group from ATP to 
selected tyrosine side chains, both on the receptor proteins themselves and on 
intracellular signaling proteins that subsequently bind to the phosphorylated 
receptor. The tyrosine phosphorylated receptor serves as a docking site for an 
array of intracellular signalling molecules, including the GTPase-activating protein 
(GAP), the p85 subunit of phosphatidyl-inositol 3’-kinase (PI3K), phospholipase C-
ץ (PLC-ץ), the protein tyrosine phosphatase SHP1, Grb2 and Src-like non-receptor 
kinases; (Rosnet, Buhring et al. 1996)Porter and Vaillancourt, 1998). These 
activated proteins then initiate serine/threonine phosphorylation cascades resulting 
in activation of transcription factors that determine a variety of cell responses, 
including cell maintenance, mitogenesis, migration and differentiation (Claesson-
Welsh, 1994). All RTKs contain an evolutionary conserved kinase domain, and the 
available crystal structures of RTK kinase domain exhibit a conserved structure 
(Hubbard 1994, Mohammadi 1996, McTigue 1999). Crystallografic studies of the 
insulin receptor (IR), solved in both active and inactive conformations, reveal a 
twofold mechanism of activation (Hubbard 1994, Hubbard 1997). In the inactive 
conformation, the activation loop of IR occupies the active site, blocking substrate 
access and/or ATP binding. Upon phosphorylation of tyrosine residues within the 
activation loop, structural changes occur that reposition the activation loop away 
from the active site, resulting in an active conformation. Mutations both in the 
activation loop and in other regions of the kinase domain have been identified in 
several RTKs, which most probably stabilize an active kinase conformation. 
- 8 -                                     
 
 
Figure 1 Protein tyrosine kinase activation mechanisms.  
Left: inactive conformation of RPTK. Right: ligand-induced receptor dimerization and 
tyrosine autophosphorylation  (From P.Blume-Jensen and T.Hunter, Nature 411:355-365, 
2001). 
 
  
3.2.2 Class III receptor tyrosine kinases: role in leukemogenesis  
The class III RTKs, which include FMS, KIT, FLT3, PDGFRα and PDGFRβ play an 
important role in normal hematopoiesis (with the exception of PDGFR). FMS, the 
receptor for the macrophage colony-stimulating factor (M-CSF), is crucial for the 
growth and differentiation of the monocyte-macrophage-osteoclast lineage (Sherr, 
1990). FLT3 and KIT are both required for the survival, proliferation and 
differentiation of hematopoietic progenitor cells, while c-kit is also important for the 
growth of mast cells, melanocytes, primordial germ cells and interstitial cells of 
Cajal. (Drexler 1996; Lyman and Jacobsen 1998)The hematopoietic functions of 
PDGFRβ are less well defined, although the receptor and its ligand probably play 
a significant role in megekaryocytopoiesis (Yang, 1997). 
 
The class III RTKs have recently been linked to the pathogenesis of an increasing 
number of hematological malignancies. KIT mutations, for example, have been 
shown to be causative in adult-type mastocytosis, as well as being associated with 
acute myeloid leukaemia and sinonasal lymphomas. Indeed, Longley et al 
(Longley, Reguera et al. 2001)have proposed a classification of mast cell disease 
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based on the nature of the c-kit mutations. FLT3 is a gene most commonly 
mutated in AML and the presence of FLT3-ITD appears to be a second strongest 
independent prognostic factor in the disease after cytogenetic. (Kiyoi, Naoe et al. 
1999) The role of PDGFRβ-fusion genes in bcr-abl-negative chronic 
myeloproliferative disorders is still unfolding, but at least eight partner genes have 
been identified. 
 
3.2.3 Mutations of FLT3 in AML 
Recent advances in genetics have shown that not only chromosome abnormalities 
but also molecular alterations are useful to characterize and subclassify acute 
myeloid leukemia (AML). For example, partial tandem duplication within the MLL 
gene (MLL-PTD) has been shown to define a subgroup of AML patients with 
unfavourable clinical outcome. (Schnittger, Kinkelin et al. 2000) 
 
FLT3 (fms-like tyrosine kinase-3; STK1, human stem cell tyrosine kinase-1 or FLK-
2, fetal liver kinase-2) is a receptor tyrosine kinase (RTK), which is known to play 
an important role in normal hematopoiesis and leukemogenesis. (Matthews, 
Jordan et al. 1991; Rosnet, Marchetto et al. 1991)FLT3 has strong sequence 
similarities to other members of the class III RTK receptor family. This protein 
family include FLT3, FMS, platelet-derived growth factor receptor (PDGFR), and 
KIT and characterized by an extracellular domain comprised of 5 
immunoglobulinelike (IG-like) domains and by a cytoplasmic domain with a split 
tyrosine kinase motif (Figure 2). 
 
 
Figure 2: FLT3 receptor. 
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IgD- immunoglobuline domain; JM- juxtamembrane domain; KI-kinase insert; TK1, TK2-
tyrosine kinase 1and 2 domains; LM-length mutation; MT-mutation 
 
 
 
FLT3 is expressed in a variety of human and murine cell lines of both myeloid and 
B-lymphoid lineage. In normal bone marrow, expression appears to be restricted 
to early progenitors, including CD34+ cells with high levels of expression of CD117 
(C-KIT). FLT3 is also expressed at high levels in a spectrum of hematologic 
malignancies including 70% to 100% of acute myelogenous leukemia (AML) of all 
FAB subtypes, B-precursor cell acute lymphoblastic leukemia (ALL), a fraction of 
T-cell ALL, and chronic myelogenous leukemia (CML) in lymphoid blast crisis. 
These data indicate that FLT3 expression may play a role in the survival or 
proliferation of leukemic blasts. (Carow, Levenstein et al. 1996; Drexler 1996)  
 
Both FLT3 overexpression and activating mutations in the FLT3 gene can be 
found in patients with AML. 20-25% of patients with AML carry activating FLT3-LM 
in the juxtamembrane domain. (Nakao, Yokota et al. 1996; Kottaridis, Gale et al. 
2001; Reilly 2002; Schnittger, Schoch et al. 2002)In another 7% mutations at 
codons 835/836 in the activation loop of FLT3 can be detected (FLT3 tyrosine 
kinase mutations, FLT3-TKD).; (Abu-Duhier, Goodeve et al. 2001; Thiede, Steudel 
et al. 2001; Yamamoto, Kiyoi et al. 2001; Thiede, Steudel et al. 2002)FLT3-LM 
have been detected in all FAB subtypes of AML, with the highest reported 
frequency in the M3 subtype, and less frequently in the M2 subtype. FLT3-LM are 
associated with leukocytosis and poor prognosis in most, (Kiyoi, Naoe et al. 1999; 
Xu, Taki et al. 1999; Rombouts, Blokland et al. 2000; Thiede, Steudel et al. 2001; 
Whitman, Archer et al. 2001; Yamamoto, Kiyoi et al. 2001)but not all studies. 
(Schnittger, Schoch et al. 2002; Thiede, Steudel et al. 2002) 
 
Recent data indicate that FLT3-LM are not present in systemic mast cell disease 
nor in a spectrum of solid tumors. FLT3-LM have not been detected in normal 
hematopoietic cells, including cord blood and bone marrow cells in which there are 
high levels of expression of FLT3. In addition to length mutations in one allele of 
FLT3 several studies have demonstrated biallelic mutations in FLT3, as well as 
patients in whom the residual wild-type allele is lost. (Kottaridis, Gale et al. 2001; 
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Whitman, Archer et al. 2001; Schnittger, Schoch et al. 2002; Thiede, Steudel et al. 
2002) 
 
FLT3-LM and FLT3-TKD mutants are constitutively autophosphorylated on 
tyrosine residues, causing activation of signal transducer and activator of 
transcription (STAT)-5 and mitogen-activated protein (MAP) kinases. (Hayakawa, 
Towatari et al. 2000; Mizuki, Fenski et al. 2000; Tse, Mukherjee et al. 2000; Tse, 
Novelli et al. 2001; Spiekermann, Dirschinger et al. 2003)In addition, transduction 
of FLT3-ITD and TKD mutants in murine IL-3-dependent cell lines, such as Ba/F3 
and 32D induces IL-3 independent growth (Fenski, Flesch et al. 2000; Hayakawa, 
Towatari et al. 2000; Mizuki, Fenski et al. 2000; Tse, Mukherjee et al. 2000; 
Yamamoto, Kiyoi et al. 2001)in vitro . Injection of 32D or Ba/F3 cells stably 
transfected with constitutively activated FLT3 into syngeneic recipient mice results 
in the development of a leukemic phenotype. (Mizuki, Fenski et al. 2000) 
Furthermore, retroviral transduction of FLT3-ITD constructs in primary murine 
bone marrow cells induces a myeloproliferative phenotype in a mouse bone 
marrow transplantant model. (Kelly, Liu et al. 2002)These data demonstrate that, 
although FLT3-ITDs have been associated primarily with AML in humans, FLT3-
ITD alone are not sufficient to induce AML in primary hematopoietic cells. 
Furthermore, a kinase-dead mutant of FLT3 in the context of FLT3-ITD abrogates 
the myeloproliferative disease, indicating an absolute requirement of FLT3 kinase 
activity for the myeloproliferative phenotype in this model. No difference in biologic 
activity of FLT3-ITD mutants have been found in cell culture or murine models, 
despite considerable variation in repeat length that ranges from several to more 
than 50 amino acids.  
 
Thus, both LM and TKD mutations in the FLT3 gene result in constitutive 
activation of the kinase activity and downstream targets including STAT5, 
RAS/MAPK, and PI3K/AKT. Expression of FLT3 activating mutations in primary 
hematopoietic cells results in a myeloproliferative phenotype, and indicates, that 
additional mutations are required for development of AML.  
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3.3 RTK inhibitors 
Although activating FLT3 mutations seem not be sufficient to cause an AML 
phenotype they represent a potential therapeutical target. Targeted inhibition of 
aberrant kinase signalling can be an effective therapeutic intervention in 
hematologic malignancies, as evidenced by hematologic and cytogenetic 
responses in chronic myelogenous leukemia (CML) and CML blast crisis patients 
treated with the BCR-ABL kinase inhibitor imatinib mesylat (STI571, Gleevec®). 
(Druker, Sawyers et al. 2001; Druker, Talpaz et al. 2001; Savage and Antman 
2002)An analogous kinase inhibitor strategy might have therapeutical potential in 
AML patients with activating mutations in the FLT3 gene.  
 
 In the past decade, many laboratories embarked on projects aimed at generating 
compounds that specifically inhibit the activity of the signalling cascades triggered 
by tyrosine kinases. Compounds with selective activity to class III RTK in vitro 
include AG1295, (Levis, Tse et al. 2001)SU5416, (Fong, Shawver et al. 1999; 
Spiekermann, Faber et al. 2002)SU5614 (Yee, O'Farrell et al. 2002; Spiekermann, 
Dirschinger et al. 2003)and CT53518. (Kelly, Yu et al. 2002)Three compounds 
(CEP-701, SU11248 and PKC412) with in vivo activity are currently evaluated in 
phase I/II clinical trials in patients with AML and have shown promising results. 
(Foran, O'Farrell et al. 2002; Foran, Paquette et al. 2002; Smith, Levis et al. 2002; 
Stone, Klimek et al. 2002) 
 
The PTK inhibitor imatinib mesylate has high clinical activity in BCR-ABL-positive 
CML in chronic phase and blast crisis as well as in BCR-ABL-positive acute 
lymphoblastic leukemia and gastrointestinal stromal tumors (GISTs) carrying 
activating KIT mutations. (Druker, Talpaz et al. 2001; van Oosterom, Judson et al. 
2001; Kantarjian, Sawyers et al. 2002)However, small molecule protein tyrosine 
kinase inhibitors may lead to drug resistance. (Sawyers 2001)Recent studies have 
indicated that resistance to imatinib may be multifactorial. (Mahon, Deininger et al. 
2000; Weisberg and Griffin 2000)In certain BCR-ABL-positive cell lines, resistance 
was associated with amplification of the fusion gene. (le Coutre, Tassi et al. 2000; 
Mahon, Deininger et al. 2000; Weisberg and Griffin 2000)Additionally, 
overexpression of the alpha 1 acid glycoprotein was detected in some resistant 
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cells. (Gambacorti-Passerini, Barni et al. 2000)At least ten different mutations in 
the ABL gene that induce imatinib resistance in vitro were found in patients with 
BCR-ABL-positive CML and ALL. (Gorre, Mohammed et al. 2001; Barthe, Gharbi 
et al. 2002; Branford, Rudzki et al. 2002; Hofmann, Jones et al. 2002; 
Roumiantsev, Shah et al. 2002; Shah, Nicoll et al. 2002; von Bubnoff, Schneller et 
al. 2002)Although FLT3 PTK-inhibitors have shown promising results in phase I/II 
clinical studies in patients with AML, it is unknown whether similar mechanisms of 
resistance exist for FLT3 PTK inhibitors. 
 
Previously, our group and others have demonstrated that the small molecule PTK 
inhibitor SU5614 is a selective inhibitor of FLT3 that induces growth arrest and 
apoptosis in FLT3 transformed cells and AML-derived cell lines expressing a 
constitutively activated FLT3. (Yee, O'Farrell et al. 2002; Spiekermann, 
Dirschinger et al. 2003) 
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4. THE GOAL OF STUDY  
 
FLT3 is known to be the most mutated gene in AML. FLT3-LM were found in 20-
25% of patients with AML and 7% of patients carry FLT3-TKD mutations. The high 
incidence of FLT3 mutations in AML makes it an attractive target for therapeutic 
interventions. The important questions here are, whether other FLT3 mutations 
can also be found in patients with AML and whether the kind of mutation in FLT3 
might be important for the sensitivity to PTK inhibitors. 
  
It was recently shown that conformational changes in the activation loop of KIT by 
the D816V mutation led to resistance of this mutant to PTK inhibitor imatinib. 
Therefore, we wanted to determine, whether FLT3-ITD and different point 
mutations in TKD of FLT3 may differ in their sensitivity to FLT3 PTK inhibitors. 
 
The development of drug resistance is major problem of chemotherapy in patients 
with AML. Previous studies on the BCR-ABL PTK inhibitor imatinib have shown 
that drug resistance may be multifactorial and include: overexpression of the 
fusion gene, development of additional mutations and overexpression of the alpha 
1 acid glycoprotein. Although FLT3 PTK inhibitors have shown promising results in 
phase I/II clinical studies in patients with AML, the similar mechanisms of drug 
resistance might occur. In this study Ba/F3 FLT3-ITD transformed cells were used 
as a model system and were incubated in the presence of the increasing 
concentration of the FLT3 PTK inhibitor. Furthermore, these cells were used to 
characterize potential mechanisms of drug resistance in vitro.  
 
It was the aim of this study to detect and characterize new mutations in the FLT3 
gene and answer the questions whether FLT3-TKD mutations can confer primary 
resistance to PTK inhibitors and whether the secondary resistance to these 
inhibitors can develop in FLT3-ITD transformed hematopoietic cell lines. 
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5. MATERIALS AND METHODS 
5.1. Chemicals 
* Corrosive; ** Toxic; *** Comburant 
Acetic acid (Merck, Darmstadt, Germany) * 
Acrylamide/Bisacrylamide 40% (Roth, Karlsruhe, Germany) ** 
Agarose (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Ammonium peroxidisulfate (APS) (Bio-rad, Munich, Germany) 
Aprotinin (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Bovine serumalbumin (BSA) (Fluka, Buch, CH) 
Ethanol (Merck, Darmstadt, Germany) *** 
Glycerin (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
HEPES (N-(2-Hydroxyethyl)piperazine-N´-(2-ethanesulfonic acid)) (Sigma-Aldrich 
Chemie GmbH, Taufkirchen, Germany) 
Leupeptin A (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
2-mercaptoethanol (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) ** 
Methanol (Merck, Darmstadt, Germany) *** 
Pepstatin A (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany) **  
Ponceaus (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Protein G-sepharose (monoclonal) (Amersham, Schweden) 
Protein A-sepharose (polyclonal) (Upstate, USA) 
Sodium Vanadate (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Sodiumdodecylsulfat (SDS)  (Bio-rad, Munich, Germany) 
Tetramethylethylendiamine (TEMED) (Serva, Heidelberg, Germany)  
Tris(hydroxymethyl)aminomethane (Tris) (Merck, Darmstadt, Germany)  
Trypan blue (Serva, Heidelberg, Germany) ** 
Tween 20 (Merk, Darmstadt, Germany) 
 
5.2 Kits 
Annexin V/Propidium Iodide (PI) kit (Alexis, Lausen, Switzerland)      
Bio-rad Protein estimation kit (Bio-rad, Munich, Germany) 
- 16 -                                     
Detection system ECL® (enhanced chemiluminescence) (Amersham Pharmacia, 
Freiburg, Germany)  
Qiagen Plasmid Maxi Kit (Qiagen, Germany) 
RNeasy Mini Kit (Qiagen, Germany) 
QIAprep-spin Miniprep Kit (Qiagen, Germany) 
OmniscriptTM Reverse Transcriptase Kit (Qiagen, Germany) 
 
 
5.3 Laboratory equipment 
Blotting chamber (Bio-rad, Munich, Germany) 
Cell culture CO2 incubator (Haereus, Rodenbach, Germany) 
Cell culture hood (Bio Flow Technik, Meckenhein, Germany)            
Centrifuges ROTIXA/P (Hettich, Tuttlingen, Germany) 
Developing machine M35X-OMAT Processor (Kodak AG, Stuttgart, Germany) 
Eppendorf ultracentrifuge 2K15 (Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany) 
FACSscan (Beckton Dickinson, Mountain View, CA) 
Fridge (4°C, -20°C) (Siemens AG, Germany)      
Fridge (-80°C)  UF80-450S (Colora Messtechnik GmBH, Lorch, Germany)                   
Gel electrophoresis systems (Bio-rad, Munich, Germany) 
Heating block BT 130-2 (HLC, Haep Labor Consult, Bovenenden, Germany) 
Liquid nitrogen tank (Cryoson, Schöllkrippen, Germany) 
Microscope (Carl Zeiss Jena, Germany) 
Nitrocellulose membranes (Sartorius, Goettingen, Germany) 
pH-meter 766 (VWR International, Ismaning, Germany) 
Rotor Ti 75 (Beckman, Palo Alto, CA) 
Shaker (Edmund Bühler, Tübingen, Germany) 
Spectophotometer Smartspec TM 3000 (Bio-rad, Munich, Germany) 
Ultracentrifuge L7-65 (Beckman, Palo Alto, CA) 
Vortex (Cenco, Breda, the Netherlands) 
Water bath (HAAKE, Karlsruhe, Germany) 
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5.4 Cells 
Suspension cells 
Cell type Description Origin 
Ba/F3 Mouse pro B cells, IL-3 dependent 
murine pro B cell line, established 
from peripheral blood BALB/c 
mouse  
 
 
DSMZ (Deutsche 
Sammlung von 
Mikroorganismen und 
Zellkulturen GmbH, 
Braunschweig, 
Germany) 
MM1 and MM6 Human acute monocytic leukemia, 
established from peripheral blood 
 
DSMZ 
 
Adherent cells 
Cell type Description Origin 
293 Human embryonic kidney, 
adherent fibroblastoid cells 
 
DSMZ 
 
 
5.5 Materials used for the cell culture 
 
5.5.1 Cell culture media and other reagents for cell culture 
RPMI 1640 (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany ) 
10% FCS (Fetal calf serum) (Biochrom AG seromed, Berlin, Germany) 
DMSO (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Penicillin/streptomycin (GIBCO BRL, Kalsruhe, Germany) 
L-glutamine (GIBCO BRL, Kalsruhe, Germany) 
Phosphate Buffer Saline (PBS) (GIBCO BRL, Kalsruhe, Germany) 
Trypan Blue (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany) 
Trypsin-EDTA (Life Technologies Invitrogen, GIBCO BRL, Kalsruhe, Germany) 
 
 
5.5.2 Culture vessels and plastic ware 
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Culture flasks and plates 
 
Container Surface area 
(cm 2) 
Medium 
required 
(ml) 
Cell 
volume of 
inoculum 
Company 
96-well flat plate 0,3 0,1 < 1x104 Nunc, Wiesbaden, 
Germany 
96-well round 
plate 
0,3 0,1 < 1x104 Nunc, Wiesbaden, 
Germany 
50 ml flask 25 5 2 x105 Greiner 
Labortechnik, 
Frickenhausen, 
Germany 
250 ml flask 75 15 6 x105 Greiner 
Labortechnik, 
Frickenhausen, 
Germany 
600 ml flask 125 30 2 x106 Greiner 
Labortechnik, 
Frickenhausen, 
Germany 
 
Other plastic material 
Centrifuge vials (15-50 ml) (Sarstedt, Nümbrecht, Germany) 
Eppendorf cups (0,5-1 ml) (Eppendorf, Hamburg, Germany)  
Freezing tubes (Nunc, Wiesbaden, Germany)  
Micropipettes, Pipettes (Gilson, Langenfeld, Germany) 
Parafilm M (American National Can, Greenwich, USA) 
 
5.6 Antibodies for Western Blot 
Anti-rabbit-HRPO (horse radish peroxidase) IgG sc-2025 (Santa Cruz 
Biotechnology, Santa Cruz, California, USA) 
Anti-mouse-HRPO IgG sc-2027 
FLT3/Flk-2 (S-18) rabbit polyclonal sc-480 
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β-Aktin mouse monoclonal 
Phospho-STAT5 (Tyr 694) rabbit polyclonal (Cell Signalling Technologies, New 
England Biolabs GmbH, Germany, Frankfut am Main) 
STAT5 rabbit polyclonal 
Phospho-p44/45 (Thr 202/Tyr 204) rabbit polyclonal 
P44/45 MAPK (ERK1/2) kinase antibody rabbit polyclonal 
 
5.7 Software 
Cellquest software (Bekton Dickison, Mountain View, CA) 
Microsoft Word, Excel, Powerpoint, Photoshop  
Winmdi 3.2 
BioEdit 
Adobe Illustrator 
Adobe Photoshop 
Tina 2.09 
 
 
 
5.8 Cell culture methods 
5.8.1 Cell culture techniques  
The mammalians cells grow attached to a substratum, like for example plastic or in 
suspension in plastic flasks. The plastic ware is obtained in sterile wraps from 
commercial suppliers and is specially prepared for use in cell culture (see Table in 
materials). All these tissue culture flasks have caps with filters which allow 
gaseous exchange, allowing maintenance of correct pH (which is monitored by the 
colour of the phenol red present in the medium) and the right percentage of CO2 
(5%). The optimal atmosphere conditions are allowed by CO2 incubator, which 
automatically control temperature and pCO2; it operates with a try of water on the 
base in an attempt to maintain more than 98% relative humidity. Temperatures of 
the incubator was set at 37°C and regurarly controlled. The use of plastic pipettes 
and special medium (very low endotoxin) was necessary to work in an endotoxin 
free condition. 
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5.8.2 Cell quantification and evaluation of viability 
An efficient way of counting cells and at same time evaluates the percentage of 
viable cells is the technique of “dye exclusion”: this test is based on the concept 
that viable cells do not take up some dyes, whereas dead cells are permeable to 
these dyes. Trypan blue is the most commonly used dye, but have the 
disadvantage of staining soluble proteins. In the cell culture however some miss-
leading situations such as recent trypsinization and freezing and thawing in 
presence of dymethylsulphoxide (DMSO) may lead to membrane leakeness.  
From each suspension cells an aliquot of 10 µl was harvested, mixed with 90 µl of  
Tryplan Blue (ratio cells:trypan blue=1:1) and counted on a counting slide under 
the microscope. The mean of at least three counts of viable cells (not stained with 
tripan blue)/quadrant was considered and multiplied to the magnitude (104) and 
the dilution factor. 
 
5.8.3 Storage of cells 
In order to minimize the cellular injury induced by freezing and thawing procedures 
(intracellular ice crystals and osmotic effects), a cryoprotective agents such as 
dimethyl sulphoxide (DMSO) or glycerol are added. A variable number of 
suspension cells between 2-10 x 106 are spin down and resuspended in a 500 µl 
10% DMSO solution (DMSO diluted in fetal calf serum). Freezing ampoules are 
cooled up before and every step is performed on ice. While short-term 
preservation of cell lines using mechanical freezers (-80°C) is possible, storage in 
liquid nitrogen (-196°C) or its vapour (-120°C) is much preferred. Rapid thawing of 
cell suspension is essential for optimal recovery. 
 
5.8.4 Proliferation assay 
Base culture medium for suspension cells (Ba/F3, MM1, MM6) was RPMI 1640 
supplemented with 10 % FCS, 1% penicillin and streptomycin + 1% L-glutamine. 
Both FCS as well as the antibiotics penicillin and streptomycin are aliquoted and 
stored at – 20°C. Serum contains complement which may interfere in virus or 
cytotoxity assays; FCS is therefore inactivated by heating it to 56°C for 45 
minutes. Serum supplies many essential factors as adhesion promoting 
components, nutrients and trace minerals, transport proteins (albumin, ferritin) and 
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other proteins. Cells were incubated at 37°C in a humidified atmosphere of 5% 
CO2 and 95% humidity.  
Cells were seeded at a density of 4x104/ml growth medium in the presence or 
absence of IL-3 and inhibitors or cytostatics as indicated. Viable cells were 
counted at 24, 48 and 72 hours in a standard hemacytometer after staining with 
trypan blue. The IC50 was defined as the concentration of inhibitor at which 50% of 
cells were viable compared to cells grown in the absence of inhibitor. 
 
5.8.5 Transfection of the 293 cells 
The cells were seeded at a density 5x105/ml. Transient transfections were then 
carried out using the calcium-phosphate co-precipitation method with a total 6µg 
DNA per 6-well (mix: 54 µl 250mM CaCl2, 54 µl HBS, pH=7.8, 6 µg DNA). 18 
hours after transfection 3 ml fresh medium was added, the cells were allowed to 
grow for another 30h and the retroviral supernatant was used for transduction of 
Ba/F3 cells.  
 
5.8.6 Stable transduction of Ba/F3 cells 
2x105/ml Ba/F3 cells were seeded in 200µl of growth medium RPMI-1640 and 
subsequently transduced once with 200µl of retroviral supernatant in the presence 
of polybrene (8µg/ml). After 4-12 hours the 1 ml of medium was added to avoid the 
toxic action of the polzbrene on the cells. The cells were sorted after 48-72 hours. 
 
5.8.7 Subculturing of adherent cells 
293 cells were maintained in Dulbecco’s modified Eagle Medium (DMEM; PAN, 
Germany) with 10% FBS. Cells growing as monolayers on plastic surfaces are 
held together and to the substratum by mucoproteins and sometimes by collagens; 
in addition, many cell monolayers require divalent cations (Ca2+, Mg2+) for their 
integrity. Thus for releasing cells from monolayers various protease solutions are 
used, sometimes in association with chelating agent. Therefore Trypsin 0,5 EDTA 
was used for subculturing of adherent cell line with following protocol: when cells 
were seen to be confluent (in a 75 cm2 flask, after 2 day of culture) old medium 
was washed out, cells were washed with PBS and incubated with 3 ml of Trypsin-
EDTA for 5-10 minutes in the incubator; prolonged exposure to trypsin should be 
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avoided as this damages the cells; therefore to inactive it, medium containing 
serum, which contain a natural trypsin inhibitor, was added. Cells were than splittet 
(subcultured) in a split ratio of 1:3 (from one 75 cm2 flask, three 225 cm2 flasks).  
 
5.8.8 Cell sorting 
The FACS-Ventage system equipped with a Turbo-Sort device (Becton Dickinson, 
San Jose, CA) was used to highly purify EGFP/EYFP-positive pool cells 48 hours 
after infection. For this purpose, the cells were washed with PBS and then diluted 
in medium containing 1µg/ml propidium jodid.   
 
5.8.9 FACS analysis 
5.8.9.1 Expression of CD135 by flow cytometry 
Ba/F3 cells were incubated for 30 minutes on ice with a mouse phycoerythrin (PE) 
labeled isotype-matched control antibody (Becton Dickinson) or CD135-PE 
(Becton Dickinson) antibody. Viable cells were analyzed using a FacsCalibur flow 
cytometer (Beckton Dickinson, San Jose, CA). 
 
5.8.9.2 Apoptosis analysis 
Assessment of apoptotic cells was carried out by annexin V/7-amino-actinomycin 
D (7-AAD) staining as recommended by the manufacturer (annexin V-
phycoerythrin (PE) apoptosis detection kit, Becton Dickinson, Heidelberg, 
Germany) using a FacsCalibur flow cytometer (Beckton Dickinson, San Jose, CA).  
 
5.8.10 Development of SU5614 resistant Ba/F3-FLT3-ITD cell lines  
Ba/F3 cells carrying the FLT3-ITD (W51) mutation were cultured in the presence 
of increasing concentrations of SU5614 (0.2 µM to 0.8µM) over a period of at least 
three months. Cells were initially cultured in the presence of 0.2 µM SU5614, with 
culture medium changes every 3-4 days, for a total 27 days. Cells were then 
cultured in 0.4µM SU5614 for an additional 35 days, and finally cells were grown in 
medium containing 0.8µM SU5614. Then cells were analyzed for drug resistance 
and further characterized. 
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5.9 BIOCHEMICAL METHODS 
5.9.3 Buffers and solutions 
 
Lysis buffer 
 
5 ml 1M HEPES pH 7,5 
3 ml 5M NaCl 
0.5 ml 200 mM EGTA 
20 ml 50% glycerol 
1 ml Triton X-100 
0.42 g NaF 
0.45gNa2P2O7x10H2O(tetra-Natriumdiphosphatdekahydrat as 
buffer) 
add 100 ml aqua dest. 
50 µl Aprotinin (200x) 
100 µl 0.1 M PMSF (350 mg/20 ml EtOH) 
100 µl 0.1 M Orthovanadat (183 g/10ml aqua dest) 
 
   10xNET 
 
1.5 M NaCl 
0.05 M EDTA pH 8 
0.5 M Tris pH 7,5 
0.5% Triton X-100 
 
   1x G-NET 
 
2.5 g gelatin 
100 ml 10xNET 
900 ml H2O  
 
   10xTBS 
 
10mM Tris pH 8 
150 mM NaCl 
 
   1xTBST 
 
100 ml 10xTBS 
0.2 % Tween 20 
Water to 1L  
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4XHNTG 
 
200 mM HEPES pH 7,5 
600 mM  NaCl 
0.4% Triton X-100 
40% glycerol 
 
Stripping 
buffer 
 
800 ml 3xTBS 
0.2% Tween 20 
H20 to 1L  
 
 
Laemmli-
Buffer 
 
187,5 mM Tris 
6% SDS 
30% glycerine 
bromphenolblue 
 
 
  Laemmli-   
  Dithiothreitol 
  (DTT) buffer 
 
 0.6 g of DTT 
 2.5 ml of Laemmli buffer 
 
 
All of chemicals were obtained from Sigma or Merck (Germany). 
 
5.9.1 Cell lysis 
Cells were incubated in lysis buffer for 30 minutes at 4°C. Whole cell lysates 
containing 100 µg protein as determined by the Bradford method were denatured 
by boiling for 5 min in SDS sample buffer, loaded into one lane and separated by 
10% SDS-PAGE. 
 
5.9.2 SDS-Polyacrylamidgelelectrophoresis PAGE 
To separate proteins according to their molecular weight (1D electrophoresis) 
protein samples (whole cell lysates) are first denaturized by boiling at 95°c for 5 
minutes in a SDS buffer;  40 to 100 µg of sample are loaded into a SDS gel and let 
run at 150 volts in a running buffer to separate electrophoretically. Proteins with 
different molecular weight and load are run differently. A marker with well-
characterized proteins allows identifying the molecular weight of unknown 
proteins. Gel must be fresh prepared; gel solution solidify and polimerize quickly 
(5-10 minutes) after giving APS and Temed. Gels can be kept in a humified 
ambience for 1-2 days. 
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5.9.4 Western Blot analysis 
After electrophoresis, proteins can be transferred to nitrocellulose membranes in a 
blotting puffer for 1hour at 75 volts and probed with appropriate Ab. To see all 
proteins transferred, the membrane can be stained shortly with Ponceau staining, 
that is a transient red staining which bind every protein. Before antibody 
incubation, the membrane has to be blocked with 0.25% gelatine in NET buffer 
(1xG-NET) for 1 hour and incubated overnight with appropriate antibodies diluted 
1:1000.  The membrane is washed 3 times for 15 minutes in TBST and then 
incubated for 1 hour at room temperature in horseradisch peroxidase (HRP) 
conjugated antibody diluted in the G-Net solution. Membrane was washed 3 times 
for 15 minutes. Detection of proteins/antibodies complexes was achieved by the 
ECL (Enhanced Luminol Reagent) system. This western blot chemiluminescence 
reagent is a non-radioactive light emitting system which detects proteins 
immobilized on a membrane, from the oxidation of luminol, which results in light 
emission at a wave length of 428 nm, captured by a autoradiography film. 
 
5.9.5 Protein quantification 
To estimate the protein concentration Bradford assay was used: the Bradford 
assay are colorimetric assay based on the differential color change of a dye in 
response to various protein concentration. The Bradford assay has the advantage 
of having slight chemical interferences, of beeing sensitive and rapid (only one 
reagent). 
Material 
and Method  
Chemical 
interference 
Company, reagents Technique procedure 
Bio-rad 
protein 
assay 
(Bradford) 
 
slight - one bottle of dye 
reagent (dye, 
phosphoric acid and 
methanol) 
stored at 4°C 
- add standard, sample, 
blank 0,8 ml 
- add 0,2 ml dye reagent 
concentrate 
- after 5 minutes measure 
OD =595 
 
Biorad purchase most of the reagents; required are also a spectophotometer and 
cuvettes for measurements. For the protein standard lyophilized preparations of 
bovine serum albumin are rehydrated in NaOH, diluted, aliquoted and stored at – 
80°C.   
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5.10 Immunological methods 
5.10.1 Immunoprecipitation 
The cells (3x107/ml) were lysed using lysis buffer. The sepharose (protein A: 
polyclonal rabbit, IgG2  or protein G: IgG1 ) was washed with prechilled 1x HNTG  
and diluted same volume of 1x HNTG, mixed by vortexing and stored at 4°C. To 
isolate antigen on antibody bead the following steps were performed: 30 µl 
sepharose, 15 µl antibody and 300 µl extracted cells were mixed and incubated on 
rotation wheel for 4 hours. Than the probes were washed to remove unbound 
proteins, then 20 µl Laemmli buffer were added and the samples were boiled at 
100°C heating block for 8 min.  
 
5.11 Molecular biology methods 
5.11.1 Buffers and solutions 
1x TBE 
 
100 ml 5x TBE 
add 500 ml aqua dest. 
 
0.5 M EDTA 
 
18.61g EDTA 
100 ml aqua dest  pH 8.0  
 
5xKCM 
 
5ml 3M KCl 
4.5 ml 1M CaCl2 
7.5 ml 1M MgCl2 
13 ml H2O 
 
LB-medium 
 
25g Luria Broth Base 
add 1L H2O  
 
LB-plates 
 
37g Luria agar 
add 1L H2O 
 
LB-medium/LB 
agar 
 
Powder obtained from Gibco BRL 
 
 
All of chemicals were obtained from Sigma (Germany), Gibco BRL(Germany) and 
Merck (Germany). Enzymes were obtained from NEB (Germany). 
 
 
- 27 -                                     
5.11.2 Polyacrylamide gel electrophoresis 
Polyacrylamide gels provide somewhat better resolution as well as significantly 
higher capacity. 
 
8%  polyacrylamide gel: 
13.3 ml acrylamide 
6.25 ml bisacrylamide 
5 ml 10xTBE 
25.5 ml aqua dest 
250 µl APS 
40 µl TEMED 
The gel solution was prepared in flask, poured between the gel and left to     
polymerize for 30 min.  After the polymerization was complete, the comb was 
removed. The lower reservoir of the electrophoresis tank was filled with 1xTBE 
buffer. The gel plates were clamped to the top of the electrophoresis tank and the 
upper reservoir was filled with 1xTBE. DC power supply was used to pre-run and 
warm the gel for 30 min at 5 V/cm (constant voltage). After that 5xloading buffer 
was added to DNA samples and molecular weight markers (to 1x final) and the 
probes were loaded on the gel. The gel was run at 5V/cm, and then stained for 5-
10 min in 0.5 µg/ml ethidium bromide. The DNA was detected using UV 
transilluminator.    
 
5.11.3 Digestion of DNA with restriction enzyme 
         0.5-1 µl Restriction enzyme (10-20 U/ul) 
         2 µl 10xRestriction enzyme buffer (Reb) 
         0.2 µl (1mg/ml) Bovine Serum Albumin (BSA, DNase free) 
         to 20 µl water 
The DNA was added and the mix was incubated at the appropriate temperature for 
required period of time (typically 2-3 hours). 
 
5.11.4 Procedure for agarose gel electrophoresis 
The correct amount of powdered agarose (Gibco BRL, Germany) was added to a 
measured quantity of electrophoresis buffer (1xTBE), than the mix was heated 
slurry in a microwave oven until agarose was dissolved. After cooling of this 
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solution to 50°C, the warm solution was poured into an. After the gel was 
completely set (ca. 30-40 min at room temperature) 1xTBE buffer was added to 
cover the gel to a depth of ca. 1 mm. The samples were mixed with 6xloading 
buffer (Promega) and loaded into the slots of the submerged gel.  After running the 
gel was incubated for 15 min in ethidium bromide solution [0,5 ug/ml] 
(Roth,Germany) and DNA was detected using UV lamp. 
 
5.11.5 Polymerase chain reaction (PCR) 
10xPCR Buffer, dNTP mix, primer solutions, and 25 mM MgCl2 were thawed on 
the ice. A master mix was prepared from 10 µl 10xPCR buffer, 10 µl 25mM MgCl2, 
2µl dNTPs and primers. Appropriate volumes of the master mix were dispensed 
into PCR tubes and template DNA was added. The PCR tubes were placed in the 
thermal cycler and programm was started. 
    
   PCR-Programm (standard): 
   94°C 2min 
_____________ 
   94°C 1min 
   58°C 1min           35-40 cycles 
   72°C 1min 
_____________ 
   72°C 7min 
     4°C ∞  
 
 
5.11.6 Preparation of the competent E.coli  
Over-night culture of E.coli was prepared, than the cells were transplanted in LB 
broth and grown up to OD600  = 0.3-0.4 (over night). After that the cells were   
centrifuged at 4000-5000 rpm for 10 min  at 4°C and the pellet was resuspended 
in 15ml ice-cold TSB-medium. 100µl aliquots of cells were transferred in 
Eppendorf-tubes and frozen down immediately in a dry-ice for 1 hour. The aliquots 
were stored at -80°C. 
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5.11.7 Transformation of competent E.coli  
The cells were thawed on the ice and 25µl of the cells were transferred in a tube. 
After that 1-10 µl DNA (0.1-1 µl) were added and also 5µl 5xKCM and water to 50 
µl. The mix was incubated on the ice for 20min and than for 10 min at room 
temperature. After addition of 250 µl of LB medium, the tubes were incubated at 
37C for one hour. After incubation 150 µl of the cells were spread on LB plate with 
appropriate antibiotics and the plates were incubated at 37° overnight. 
   
5.11.8 DNA purification 
 
5.11.8.1 Purification of genomic DNA  
(DNeasy protocol for cultured animal cells, QIAGEN) 
The appropriate number of cells (max. 5x106) was centrifuged for 5 min at 300xg. 
The pellet was resuspended in 200 µl PBS. 20 µl proteinase K and 200 µl Buffer 
AL were added to the sample, mixed by  vortexing and incubated at 70°C for 10 
min. 200 µl ethanol (96-100%) were added to the sample. The mixture was placed 
into the DNeasy spin column placed in a 2 ml collection tube and centrifuged at 
6000xg for 1 min. The DNeasy spin column was placed in a 2 ml collection tube, 
500 µl Buffer AW1 were added and centrifuged at 6000xg for 1 min. Than 500 µl 
Buffer AW2 were added and centrifuged for 3 min at a full speed to dry the 
DNeasy membrane. After that the DNeasy spin column was placed in a clean 1,5 
ml or 2 ml microcentrifuge tube, 200 µl Buffer AE (elution buffer) were added 
directly onto the DNeasy membrane. After incubation at RT for 1 min the DNA was 
eluted. 
 
 5.11.8.2 Mini-preparation 
(QIAprep Spin Miniprep Kit Protocol) 
This protocol was designed for purification of up to 20µl of high-copy plasmid DNA  
from 5 ml overnight cultures of E.coli in LB (Luria-Bretani) medium. 
Pelleted bacterial cells were resuspend in 250µl of Buffer P1 and transferred to a 
microfuge tube. 250 µl of Buffer P2 were added. 350 µl of Buffer N3 were added 
and tubes were centrifuged for 10 min.  The supernatants were applied to the 
QIAprep column by pipetting and centrifuged for 30 sec. QIAprep spin column 
were washed by adding 0.75 ml of Buffer PE and centrifuged for 30 sec and then 
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for an additional 1 min to remove residual  wash buffer. Further QIAprep spin 
column were placed in a clean 1.5-ml microfuge tubes. To eluate DNA, 50µl of 
Buffer EB (10mM Tris-Cl, pH 8.5) were added and centrifuged for 1 min.  
 
5.11.8.3 Maxi-preparation 
(using the EndoFree Plasmid Maxi Kit from QIAGEN) 
A single colony was picked from a freshly streaked selective plate and incubated 
first in 2-5 ml LB medium containing the appropriate selective antibiotic for 1 hour, 
then in 100 ml for additional 12-16 hours at 37C with vigorous shaking (300rpm). 
After that the bacterial cells were harvested by centrifugation at 6000xg for 15 min 
at 4°C and resuspended in 10 ml Buffer P1. Then10 ml Buffer P2 were added and 
incubated at room temperature for 5 min. After that 10 ml chilled Buffer P3 were 
added to the lysate and whole mix was poured into the barrel of the QIAfilter 
Cartridge and incubated at room temperature for 10 min. 
After filtration of the cell lysate into a 50 ml tube, 2.5 ml Buffer ER were added and 
incubated on ice for 30 min. A QIAGEN-tip 500 were equalibrated by applying 10 
ml Buffer QBT. After that the filtered lysate was placed to the QIAGEN-tip and the 
QIAGEN-tip were washed with2x30 ml QC buffer. DNA elution was performed with 
15 ml Buffer QN. DNA was precipitated by adding 10.5 ml room-temperature 
isopropanol and centrifuged at 15,000xg for 30 min at 4C. DNA pellet was washed 
with 5 ml of endotoxin-free, room-temperature 70% ethanol and centrifuged at 
15,000xg for 10 min. The pellet was air-dried for 5-10 min, and redissolved in a 
suitable volume of endotoxin-free Buffer TE. 
 
5.11.9 RNA isolation, RNeasy Mini Protocol for isolation of total RNA from 
animal cells.  
RNeasy kit (Qiagen, Hilden, Germany) 
The cells (no more than 1x106) were harvested.  350 µl Buffer RLT (lysis buffer) 
were added to the cells.  1 volume (350 or 600 µl) of 70% ethanol to the 
homogenized lysate was added. 700 µl of each sample were placed into each 
RNeasy column placed in a 2 ml collection tube and centrifuged for 15s at 8000xg. 
700 µl Buffer RW1 were added to the RNeasy column and centrifuged for 15s at 
8000xg. The RNeasy column was transferred into a new 2 ml collection tube. 500 
µl Buffer RPE were placed onto the RNeasy column and centrifuged for 15s at 
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8000xg. After that another 500 µl Buffer RPE were placed to the RNeasy column 
and centrifuged for 2 min at 8000xg to dry the RNeasy silica-gel membrane.  
To elute, the RNeasy column were transferred  to a new 1.5 ml collection tube, 30 
µl RNase-free water was added directly onto RNeasy silica-gel membrane and 
centrifuged for 1 min at 8000xg . 
 
5.11.10 Reverse transcription RNA to cDNA 
(using Dilute QIAGEN kit Omniscript Reverse Transcriptase, Hilden, Germany) 
The template RNA solution was thawed on ice. The primer solutions, 10xBuffer 
RT,   dNTP Mix, and RNase-free water were thawed at room temperature and 
than stored on ice immediately after thawing. Each solution was mixed by 
vortexing, and centrifuged briefly to collect  residual liquid from the sides of the 
tubes.  RNase inhibitor was diluted to a final concentration of 10 units/µl in ice-cold 
1x Buffer RT, mixed carefully by vortexing for no more than 5 sec, and centrifuged 
briefly to collect residual liquid from the sides of the tubes. Fresh master mix was 
prepared (2µl 10x RT Buffer, 2 µl dNTP Mix, 2µl Oligo-dT  primer, 1µl RNase 
inhibitor, 1µl Omniscript Reverse transcriptase and water variable). After that 
template RNA were added to the individual tubes containing the master mix and 
incubated for 60min at 37°C. For analysis of shorter cDNAs by PCR or other 
downstream enzymatic applications, Omniscript Reverse Transcriptase was 
inactivated by heating the reaction mixture to 93°C for 5 min followed by rapid 
cooling on ice. 
 
5.11.11 In vitro mutagenesis 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) 
Mutagenic primer design: 
The primers were designed between 25 and 45 bases in length, with a melting 
temperature of ≥75°C. 
Tm=81.5=0.41(%GC)-675/N-%mismatch 
• N is the primer length in bases 
• Values for %GC and %mismatch are whole numbers 
The desired mutation was closed to the middle of the primer with 10-15 bases of 
template-complementary sequence on both sides. 
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Optimum primers had a minimum GC content 40% and terminated on one or more 
C and G bases at the 3’-end. 
 
Mutagenesis reaction: 
  10xPCR Buffer, dNTP mix, primer solutions, and 25 mM MgCl2 were thawed. A 
master mix (35µl H2O, 5µl 10xPCR buffer, 3µl Quick Solution, primers) was 
prepared. After that appropriate volumes were dispensed into PCR tubes. Then 
template DNA and 1µl dNTPs were added to the individual tubes, containing the 
master mix. After that the PCR tubes were placed in the thermal cycler and the 
program was started. 
 
   Cycling parametrers (standard): 
   94°C 2min 
   80°C 1min        - hot start 
_____________ 
   94°C 1min 
   56°C 1min           4 cycles 
   72°C 1min 
_____________ 
   94°C 1min 
   58°C 1min           14 cycles 
   72°C 1min 
_____________ 
   72°C 7min 
     4°C ∞  
 
 
 
 
 
 
 
 
- 33 -                                     
5.12 Primer 
Mutagenesis Primer :  
FLT3 V592A    
5’-CAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGCTGATTTC-3’ 
 
FLT3 840GS 
5’- GATATCATGAGTGATTCCGGATCCAACTATGTTGTCAGG -3’ 
 
FLT3 D835H 
5’- GACTTTGGATTGGCTCGACATATCATGAGTGATTCCAACC -3’ 
 
FLT3 D835Q 
5’- GACTTTGGATTGGCTCGACAGATCATGAGTGATTCCAACC -3’ 
 
FLT3 D835V 
5’-GACTTTGGATTGGCTCGAGTTATCATGAGTGATTCCAACC -3’ 
 
FLT3 D835Y 
5’-GACTTTGGATTGGCTCGATATATCATGAGTGATTCCAACC -3’ 
 
 
FLT3 D835N 
5’- GACTTTGGATTGGCTCGAAATATCATGAGTGATTCCAACC -3’ 
 
FLT3 Y842H 
5’-GAGTGATTCCAACCATGTTGTCAGGGGCAATG-3’ 
 
 Primers for FLT3 sequencing: 
pMSCV                 5’- CCCTTGAACCTCCTCGTTCG-3’        1-260bp of FLT3 
cDNA  
FLT3 2                     5’-AAGACCTCGGGTGTGCGTTG-3’        260-600 
 
FLT3 3                     5’-ACGCCCTGGTCTGCATATC-3’           600-940 
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FLT3 843F               5’- CGGGCTCACCTGGGAATTAG-3’      940-1280 
 
FLT3 5                     5’-TTTGCAATCATAAGCACCAGC- 3’      1280-1620 
 
FLT3 6                     5’-ATACAATTCCCTTGGCACATC-3’        1620-1960 
 
FLT3 7                       5’-AACGGAGTCTCAATCCAGG-3’           1960-2300 
 
FLT3 2205F               5’-CAGCATGCCTGGTTCAAGAG-3’         2300-2640 
 
FLT3 9                     5’-AGGCATCTACACCATTAAGAG-3’       2640-2980 
 
 
 
5.13 Plasmids 
 
FLT3-WT 
FLT3-W51    
 Provided by G.Gilliland, Howard Hughes Medical School and 
 Institute and Bringham and Women’s Hospital Harvard 
Institute of Medicine, Harvard Medical School, Boston, MA 
FLT3 
D835H/Q/V/Y, 
FLT3-V592A, 
FLT3-840GS 
Prepared in K.Spiekermann group, CCG-Leukemia, GSF 
National Research Center for Environment and Health, 
Munich, Germany 
MSCV-IRES-
EYFP/EGFP 
 Retroviral expression vector that contains an IRES site and 
allows translation of EYFP and the construct from the same 
transcript. Provided by R.K. Humphries, The Terry Fox 
Laboratory, Vancouver, University of British Columbia, 
Canada 
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6. RESULTS 
 
6.1 FLT3-TKD and FLT3-LM in patients with AML 
Bone marrow or blood samples from 60 adult patients with newly diagnosed and 
untreated AML were analysed. All were diagnosed as having AML according to 
standard French-American-British (FAB) and WHO criteria and were referred to 
our clinic for central cytomorphologic and cytogenetic diagnostics. The studies 
abide by the rules of the local internal review board and the tenets of the revised 
Helsinki protocol. Genomic DNA from the patients was screened for activating 
FLT3-LM and TKD-mutations to investigate the frequency of these mutations in 
AML (summarized in Table 3).  
 
 
Table 3: Frequency of FLT3-TKD and FLT3-LM in patients with AML 
The frequency of FLT3-TKD mutations (column 3) and FLT3-LM (column 4) mutations is 
given in different morphologically defined AML-subgroups according to the FAB-
classification. The percentage of patients carrying either the FLT3-TKD mutation or the 
FLT3-LM is listed in column 5.  
 
The loss of the EcoRV restriction site at codon 835/836 by mutations (Yamamoto, 
Kiyoi et al. 2001)and the previously described PCR-based assay for detection of the 
FLT3-LM (Kiyoi, Naoe et al. 1999)was used for a mutation screen. Abnormal 
restriction profiles at codon D835/836 were found in 6/60 (10%) of AML patients. 
The presence of a TKD mutation was confirmed in all cases by nucleotide 
sequencing. The mutations found at D835 were genetically heterogeneous and 
resulted in substitution of D835 by glutamine (n=2), tyrosine (n=1), valine (n=1), 
alanine (n=1) and histidine (n=1). When related to the FLT3 length mutations 
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which were found in 27/60 (45%) of patients, both genetic alterations occurred 
independently and none of the patients carried both mutations.  
 
6.2 A new and recurrent mutation of FLT3: FLT3-840GS 
 
6.2.1 Detection of the FLT3-LM in exon 20 
We used a PCR based method to screen for mutations of codons D835/836 in 
patients with AML. After gel electrophoresis of the amplification products from 
exon 20 we observed an additional PCR fragment which was slightly larger than 
the PCR product of the wildtype allele in two patients (Figure 3). 
 
 
 
Figure 3: Detection of the FLT3-LM in exon 20 in AML after agarose gel 
electrophoresis. 
Detection of the length mutation in exon 20 after conventional agarose gel electrophoresis 
of PCR-products from cDNA and genomic DNA. M: Molecular weight standard, H20: water 
control, C: Patient without exon 20 mutation, P1/2: patient 1/2 with the length mutation in 
exon 20. 
 
RT-PCR was repeated more than ten times with different aliquots of RNA as well 
as cDNA and always gave the same results. Sequencing revealed an insertion of 
6 nucleotides between the codons S840 and N841 just five amino acids (AA) 
downstream of D835. These nucleotides generated a BamHI restriction site which 
was confirmed by BamHI digestion and gel electrophorese. For this purpose, the 
TKD2 of FLT3 was amplified by PCR, than PCR product was digested with BamHI 
and detected on the gel (Figure 4). The DNA from FLT3-WT was used as a 
control.  
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Figure 4: Confirmation of the mutation by BamHI digestion after polyacrylamide gel                
electrophoresis.  
M: molecular weight standard, MT: patient with mutation, WT: two patients without 
mutation, H20: water control. The PCR products were digested with BamHI and detected 
after polyacrylamid gel electrophoresis. 
 
 
The Figure 5 shows the schematic presentation of the FLT3-840GS mutation. 
 
 
Figure 5: Schematic presentation of the FLT3-840GS mutation.  
WT- FLT3 wild type; MT- mutation; TM- transmembrane domain; JM-juxtamembrane 
domain; PTK1 and 2 – protein tyrosine kinase domain 1 and 2, respectively; KI- kinase 
insert. 
 
For patient 1 a DNA sample was available and the mutation could be shown also 
at the genomic level by PCR, confirming the presence of the mutation (Figure 4). 
The respective mutation was not detected in further 357 unselected AML pts. 
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Additional screening for frequent genetic mutations in these two patients showed 
no further activating mutations of FLT3, NRAS, KIT or MLL (Table 4).  
 
 
Table 4: Clinical data and alterations of other molecular markers in the two patients 
carrying the FLT3-840GS mutation. FLT3-LM, length mutations in the JM-region of 
FLT3; FLT3D835, mutations in codons 835/836; KIT D816, point mutations in codon 816; 
NRAS, activating point mutations in codons 12, 13 and 61; MLL-PTD, MLL-partial tandem 
duplication. 
 
 
6.2.2 Generation of FLT3-840GS Ba/F3 cell lines 
To analyze the transforming potential of the FLT3-840GS mutant, Ba/F3 FLT3-
840GS, FLT3-WT, FLT3-ITD and mock-expressing cells were generated. Ba/F3 
cells were transduced with the pMSCV-IRES-EYFP retroviral expression vector 
that contains an IRES site and allows translation of EYFP and the FLT3 construct 
from the same transcript. Transduced EYFP-positive cells were sorted by FACS 
on the basis of EYFP fluorescence and were expanded in the presence of IL-3. As 
a positive control we generated Ba/F3 cells expressing the FLT3-ITD (W51) 
mutant. (Spiekermann, Dirschinger et al. 2003) 
 
As shown in Figure 6, the FLT3-840GS expressing Ba/F3 cells grew factor-
independently, whereas mock-expressing cells were unable to proliferate in the 
absence of IL-3.  
 
- 39 -                                     
 
Figure 6: Transforming potential of the FLT3-840GS mutant.  
Ba/F3 cells transduced with either pMSCV-EYFP-IRES-FLT3-840GS or empty vector 
(pMSCV-EYFP-IRES, mock) were grown in the absence or presence of IL-3 as indicated. 
Results represent means ± SD of three independent experiments.  
 
 
6.2.3 FLT3 expression and hyperphosphorylation in FLT3-840GS transformed 
Ba/F3 cells. 
To confirm the identical expression level of all FLT3 constructs flow cytometry 
analysis was performed. For this purpose, FLT3WT, FLT3ITD, FLT3-840GS or empty 
vector expressing Ba/F3 cells were incubated with a mouse isotype-matched control 
antibody (open histograms) or CD135-phycoerythrin (filled histograms) antibody. Viable 
cells were analyzed using a FacsCalibur flow cytometer (Figure 7). 
 
Figure 7: FLT3 expression in Ba/F3 MIY (vector), FLT3-WT, FLT3-ITD or FLT3-840GS 
expressing cells. 
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Given the profound biological differences between the FLT3-WT and FLT3-MT (TKD or 
LM) constructs, we next analyzed the FLT3 receptor activation. Lysates from Ba/F3 cells 
were immunoprecipitated with αFLT3-antibody and analyzed by Western blot using an 
antiphosphotyrosine (αPY) antibody, stripped and reblotted with αFLT3 antibody. Our 
data show, that the FLT3-840GS and the FLT3-ITD receptors were hyperphosphorylated 
in contrast to the FLT3-WT receptor (Figure 8).  
 
 
 
Figure 8: The FLT3-840GS mutant receptor is hyperphosphorylated in Ba/F3 cells. 
 
 
6.2.4 Transforming potential of the FLT3-840GS mutant 
The detailed analysis of the growth characteristics of FLT3-840GS Ba/F3 cells showed a 
significantly slower growth rate compared to the FLT3ITD expressing cells. To analyze, 
whether Ba/F3 cells expressing FLT3-840GS can achieve a maximum proliferation rate, 
the cells were grown for 72h in the absence or presence of different concentrations of IL-3 
as indicated. Ba/F3 cells expressing FLT3-WT or FLT3-ITD were used as a control. The 
growth of FLT3ITD expressing Ba/F3 cells at 72h was defined as 100%. Our data clearly 
show that for maximal proliferation, the FLT3-840GS expressing cells required additional 
IL-3 at concentrations as low as 0.1 ng/ml  (Figure 9).  
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Figure 9: For maximal proliferation the FLT3-840GS expressing cells require 
additional IL-3. 
Results represent means ± SEM of three independent experiments. 
 
 
 
6.2.5 FLT3-840GS activates the MAPK-STAT signalling pathway of FLT3 
To identify common signalling pathways that specifically transduce the 
transforming signals of the FLT3-840GS- mutated receptor, we analyzed the 
activity of this mutant to activate STAT5 and MAPK. Using phosphospecific 
antibodies, we found that FLT3-840GS induced a strong activation of MAPK 
(Figure 10A), but only a weak activation of STAT5 (Figure 10B).  
 
6.2.6 Sensitivity of the new mutation FLT3-840GS to the selective PTK 
inhibitor SU5614 
We next asked whether the FLT3-840GS mutant is sensitive to the growth 
inhibitory activity of SU5614, a FLT3 PTK inhibitor. (Spiekermann, Dirschinger et 
al. 2003) Our results clearly show that SU5614 induced a growth inhibition of the 
FLT3-840GS as well as of the FLT3ITD transformed Ba/F3 lines in the absence, 
but not in the presence of IL-3 (Figure 11). 
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Figure 10: Activation of FLT3 downstream targets (STAT5 and MAPK) in Ba/F3 cells 
transformed with FLT3-ITD and FLT3-840GS mutants. 
A. Lysates were prepared from Ba/F3 cells expressing mock, FLT3-WT, FLT3-ITD, FLT3-
840GS constructs after IL-3 stimulation (for 5 min, RT) and without stimulation (+ and -). 
Immunoblotting of lysates was performed with anti-pMAPK and anti-MAPK antibodies. 
B. Lysates were prepared from Ba/F3 cells expressing mock, FLT3-WT, FLT3-ITD, FLT3-
840GS constructs. Immunoblotting of lysates was performed with anti-pSTAT5 and anti-
STAT5 antibodies. 
 
 
 
Figure 11: Sensitivity of the FLT3-840GS mutant to the growth inhibitory activity of 
the FLT3 PTK inhibitor SU5614  
Dose-responses curves of the inhibitory activity of SU5614 in Ba/F3 FLT3-ITD and FLT3-
840GS cells after 72h of incubation. Ba/F3 cells expressing different FLT3-constructs 
were seeded at a density of 4x104 cells/ml in the absence or presence of different 
concentrations of SU5614. Viable cells were counted after 72 h by trypan blue exclusion.  
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6.3 A new point mutation in the juxtamembrane region of the 
       FLT3: FLT3-V592A 
 
6.3.1 MM1 and MM6 cell lines 
MonoMac1 and MonoMac6 cell lines were established from the peripheral blood of 
a 64-year-old man with leukemia (AML FAB M5) (DSMZ). Previous studies have 
shown that these cell lines express an autophosphorylated FLT3 receptor 
sensitive to SU5614. (Spiekermann, Dirschinger et al. 2003) 
To further clarify the mechanisms of constitutive FLT3 activation in MM6 and MM1 
cells, the complete FLT3 cDNA was sequenced. Both MM1 and MM6 cells carry a 
point mutation in the JM region, which result in the substitution of valine by alanine 
at position 592 (V592A) (Figure 12).  
 
 
  
 
 
Figure 12: Schematic presentation of the FLT3-V592A mutation.   
 
 
 
6.3.2 Generation of FLT3-V592A expressing Ba/F3 cells 
 
To analyze the transforming potential of the FLT3-V592A mutation, Ba/F3 FLT3-
V592A cells were generated. Overexpression of this mutant in IL-3-dependent 
Ba/F3 cell lines resulted in factor-independent growth, thereby showing the 
transforming activity of this mutant (Figure 13). Compared with FLT3-ITD-
expressing cells, FLT3-V592A-Ba/F3 cells showed a slightly slower growth rate. 
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Figure 13:  Ba/F3 cells transduced with either the pMSCV-EYFP-IRES-FLT3-WT/ITD or 
V592A construct were grown in the absence or presence of IL-3 as indicated. Results 
represent means ± SD of three independent experiments.  
 
 
 
6.3.3 Sensitivity of the new mutation FLT3-V592A to the selective PTK 
inhibitor SU5614 
 
The selective PTK inhibitor SU5614 has been reported to inhibit the growth of 
FLT3-ITD and FLT3-D835Y carrying Ba/F3 cells. (Yee, O'Farrell et al. 2002; 
Spiekermann, Dirschinger et al. 2003)To analyze the sensitivity of the FLT3-
V592A mutant to SU5614, FLT3-V592A expressing Ba/F3 cells were cultured in 
the presence of different concentrations of SU5614 for 72 hours.  FLT3-V592A 
and FLT3-ITD showed a similar and high sensitivity to SU5614 (IC50 =0.1) (data 
not shown). 
 
 
6.3.4 Importance of the Y589/591 tyrosine residues in FLT3-V592A signalling 
 
FLT3 is constitutively activated by the substitution of Ala for Val at codon 592 in 
the juxtamembrane domain, and this mutation confers a factor independent growth 
on IL-3-dependent cell line. To examine how FLT3-V592A yields oncogenic signal 
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transduction, we constructed the expression vector pMSCV-YEFP carrying FLT3 
mutants that encode the Y→F substituted FLT3-V592A or FLT3-D835Y. To 
examine further the effect of Y→F substitution at codons 589 and 591 on the 
factor-independent growth by FLT3-V592A and FLT3-D835Y, these constructs 
were transfected into IL-3 dependent Ba/F3 cell lines. As controls, Ba/F3 cells 
were also transfected with the expression vector carrying FLT3-V592A and FLT3-
D835Y. 
As shown in Figure 14A, Ba/F3 FLT3-D835Y-Y589/591F cells showed factor-
independent growth at an almost similar level to Ba/F3 FLT3-D835Y cells.  
 
Ba/F3 FLT3-V592A Y589/591F cells also proliferated in a factor-independent 
manner, but their magnitude of proliferation was lower than that of Ba/F3 FLT3-
V592A cells (Figure 14B). 
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Figure 14:  Ba/F3 cells transduced with either pMSCV-EYFP-IRES-FLT3-D835Y, D835Y-
Y589/591F (A) or V592A, V592A-Y589/591F (B) were grown in the absence or presence 
of IL-3 as indicated. Results represent means ± SD of three independent experiments.  
 
 
These findings indicate that tyrosines at codons 589 and 591 are important for full 
transformation activity of the FLT3-V592A, but not of the FLT3-D835Y mutant 
receptor. 
 
 
 
6.4 Sensitivity of the different FLT3-TKD point mutations to the 
PTK inhibitor SU5614 
 
                
6.4.1 The FLT3-TKD mutants D835Y/V/H/Q induce IL-3 independent growth in  
         Ba/F3 cells  
 
In order to analyze the transforming potential of FLT3-TKD mutants in IL-3 
dependent Ba/F3 cells, we generated FLT3-D835 Y/V/H/Q expressing cell lines. 
Ba/F3 cells were transduced with the pMSCV-IRES-EYFP retroviral expression 
vector that contains an IRES site and allows translation of EYFP and the FLT3 
construct from the same transcript. Transduced EYFP-positive cells were sorted 
by FACS on the basis of EYFP fluorescence and were expanded in the presence 
of IL-3. Identical expression level of all FLT3 constructs was confirmed by flow 
cytometry and by Western blot after immunoprecipitation (IP) with a FLT3 specific 
antibody (data not shown). As a positive control we generated Ba/F3 cells 
expressing the FLT3-ITD (W51) mutant. (Spiekermann, Dirschinger et al. 2003) 
As described previously, the FLT3-ITD, but not the FLT3-WT construct conferred 
IL-3 independent growth. All FLT3-D835 mutant-transduced Ba/F3 cell lines were 
able to grow in the absence of IL-3 at a growth rate comparable to that of the 
FLT3-ITD expressing cells (Figure 15).   
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Figure 15:  Ba/F3 cells transduced with either pMSCV-EYFP-IRES-FLT3-WT/ITD or 
D835H/Q/V/Y were grown in the absence or presence of IL-3 as indicated. Results 
represent means ± SD of three independent experiments.  
 
  
 
6.4.2 FLT3-TKD mutants activate the STAT5 and MAPK signaling pathways 
 
We and others have previously shown that FLT3-ITD and TKD mutants induce a 
constitutive STAT5 and MAPK activation in Ba/F3 or 32D cells. (Hayakawa, 
Towatari et al. 2000; Mizuki, Fenski et al. 2000; Tse, Mukherjee et al. 2000; Tse, 
Novelli et al. 2001; Spiekermann, Dirschinger et al. 2003)To characterize the 
signaling properties of FLT3-TKD mutants, we analyzed lysates from Ba/F3 cells 
expressing the FLT3-WT, -ITD or -D835Y/V/H/Q constructs. Using an anti-
phosphotyrosine antibody, we could clearly show that the FLT3-D835Y/V/H/Q-
transduced Ba/F3 cells express a hyperphosphorylated FLT3 receptor (data not 
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shown). Furthermore, we analyzed the ability of FLT3-TKD mutants to activate 
STAT5 and MAPK, two known downstream targets of FLT3-ITD mutants. For this 
purpose, crude lysates from Ba/F3 cells expressing the FLT3-D835Y/V/H/Q 
mutants were analyzed by phosphospecific antibodies against STAT5 and MAPK. 
As shown in Figure 16 all FLT3-D835 mutants induced a strong constitutive 
activation of STAT5 and MAPK at levels comparable to the FLT3-ITD construct. 
 
 
Figure 16: Activation of FLT3 downstream targets (STAT5 and MAPK) in Ba/F3 cells 
transformed with FLT3-ITD and TKD mutants 
Lysates were prepared from Ba/F3 cells expressing the FLT3-WT, FLT3-ITD, FLT3-
D835H/Q/V/Y constructs. Immunoblotting of lysates was performed with anti-pSTAT5 and 
anti-STAT5 (A), anti-pMAPK and anti-MAPK antibodies (B).  
 
 
These data clearly demonstrate that all FLT3-TKD mutants analyzed in our study 
have transforming potential and induce a hyperphosphorylation of FLT3. STAT5 
and MAPK represent common downstream targets of the constitutively active 
FLT3-ITD and FLT3-TKD-mutant receptors.  
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6.4.3 FLT3-TKD mutants differ significantly in their sensitivity to the growth   
            inhibitory activity of the FLT3 PTK inhibitor SU5614  
 
We and others have previously reported that the PTK inhibitor SU5614 inhibits the 
growth of FLT3-ITD and FLT3-D835Y carrying Ba/F3 cells. (Yee, O'Farrell et al. 
2002; Spiekermann, Dirschinger et al. 2003)To analyze the sensitivity of different 
FLT3-D835 mutants to SU5614 we cultured FLT3- D835Y/V/H/Q-expressing 
Ba/F3 cells in the presence of different concentrations of SU5614 for 72 hours. 
Ba/F3 cells expressing different FLT3-constructs were seeded at a density of 
4x104 cells/ml in the absence or presence of different concentrations of SU5614. 
Viable cells were counted after 72 h by trypan blue exclusion. As shown in Figure 
17A, FLT3-TKD mutants differ significantly in their sensitivity to the inhibitor. FLT3-
D835Y and FLT3-ITD cells show a similar and high sensitivity to SU5614 
(IC50=0.2µM and 0.1µM respectively).  
 
 
Figure 17: FLT3-TKD mutants differ significantly in their sensitivity to the growth 
inhibitory activity of the FLT3 PTK inhibitor SU5614  
A. Dose-responses curves of the inhibitory activity of SU5614 in Ba/F3 FLT3-ITD and 
FLT3-TKD cells after 72h of incubation. The growth of cells that were incubated without 
inhibitor was defined as 100%. Values represent means and standard errors from three 
independent experiments. B. Sensitivity of FLT3-ITD and TKD mutants to SU5614. Values 
represent means and standard errors from three independent experiments.  
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In contrast, the FLT3-D835Q and D835V mutants were significantly less sensitive 
to the inhibitor (IC50=0.4 and 1µM respectively), and the FLT3-D835H was the 
most resistant mutant (IC50>10µM). At concentrations of 1µM of inhibitor FLT3-ITD 
cells showed a viability of 3% compared to 10% (FLT3-D835Y), 38% (FLT3-
D835Q), 52% (FLT3-D835V) and 78% (FLT3-D835H) after 72 hours of incubation 
(Figure 17B).  
These data demonstrate that FLT3-TKD mutants differ significantly in their 
sensitivity to the FLT3 PTK inhibitor SU5614 in the following order: D835Y > 
D835Q > D835V > D835H.  
 
 
 
6.4.4 SU5614 induces apoptosis in FLT3-ITD and FLT3-D835Y, but not in               
FLT3-D835H transformed cells 
 
To further characterize the mechanisms of primary resistance of the FLT3-D835H 
mutant to SU5614, we analyzed induction of apoptosis after inhibitor treatment of 
FLT3-ITD, D835Y and D835H transformed Ba/F3 cells with SU5614. 
 Figure 18A (upper panel) shows that FLT3-ITD transformed cells underwent rapid 
apoptotic cell death after exposure to increasing concentration of SU5614 after 24 
hours as measured by the expression of annexin V/7-AAD. FLT3-D835Y cells 
show the same level of sensitivity to SU5614 (IC50 = 0.1µM) (Figure 18A, middle 
panel), but not the FLT3-D835H cells (Figure 18A, bottom panel). In the presence 
of 5µM of SU5614 FLT3-D835H cells show only 18% apoptotic cells in comparison 
to FLT3-ITD (63%) and FLT3-D835Y cells (60%). A representative experiment is 
shown in Figure 18B and clearly demonstrates that SU5614 at a concentration of 
5µM induces apoptosis in 11.6% of D835H (lowest panel) cells compared to 
60.2% and 78.3% in FLT3-D835Y (middle panel) and FLT3-ITD (upper panel) 
expressing Ba/F3 cells, respectively. 
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Figure 18:  SU5614 induces apoptosis in FLT3-ITD and FLT3-D835Q/V/Y, but not in 
FLT3-D835H cells. 
A. and B. Ba/F3 cells transduced with the FLT3-ITD, FLT3-D835Y or FLT3-D835H 
constructs were incubated with different concentrations of SU5614 for 24 hours and were 
analyzed by flow cytometry after staining with annexin V-PE and 7-AAD. Representative 
dot plots from one out of three independently performed experiments are shown. 
 
 
6.4.5 The FLT3 PTK inhibitor SU5614 downregulates autophosphorylation of  
          the FLT3-ITD, but not the FLT3-D835H receptor mutant 
 
It was recently shown that SU5614 inhibits phosphorylation of the FLT3-ITD 
receptor and downregulates STAT5 and MAPK phosphorylation. (Yee, O'Farrell et 
al. 2002; Spiekermann, Dirschinger et al. 2003)To confirm the resistance of FLT3-
D835H cells to SU5614 on the level of individual signaling pathways we analyzed 
the activation of FLT3, MAPK and STAT5 after incubation with SU5614.  
For this purpose, 293T cells were transiently transfected with either the FLT3-ITD 
or the D835H construct. Lysates were prepared after incubation of the cells with 
SU5614 (0, 1, and 10µM) for 4 hours and immunoprecipitated using a polyclonal 
anti-FLT3 antibody. The phosphorylation of FLT3 was analyzed by Western blot 
analysis using a monoclonal anti-phosphotyrosine (α-PY) antibody. As shown in 
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Figure 19A, SU5614 induced an efficient dephosphorylation of the FLT3-ITD 
receptor at a concentration of 1µM (38.5% of control, defined as the FLT3 
phosphorylation in the absence of SU5614 compared to basal levels of FLT3 
measured by densitometry). In contrast, the D835H mutant was still strongly 
hyperphosphorylated (92.7%) in the presence of 1µM SU5614. At concentrations 
of 10µM SU5614 the FLT3-ITD construct was almost completely 
dephosphorylated (7.4%), whereas a significant autophosphorylation was still 
detectable in FLT3-D835H transfected cells (46.4%).  
We further analyzed the effects of SU5614 on the activation of two important 
downstream signalling pathways activated by FLT3-LM/TKD mutants. In the 
presence of 1µM of SU5614 STAT5 phosphorylation in Ba/F3 FLT3-ITD cells was 
almost completely inhibited (Figure 19B). In contrast, in Ba/F3 FLT3-D835H 
expressing cells STAT5 was only slightly dephosphorylated in the presence of this 
concentration of inhibitor. The incubation of the cells with 10µM of SU5614 
produced an almost complete inhibition of STAT5 phosphorylation in both Ba/F3 
FLT3-ITD and D835H transduced cell lines.  
 
 
Figure 19: The FLT3 PTK inhibitor SU5614 downregulates autophosphorylation of 
the FLT3-ITD, but not FLT3-D835H receptor mutants 
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A. Tyrosine phosphorylation of FLT3 was determined by Western blot analysis using a 
monoclonal anti-PY antibody and identical loading was confirmed by reblotting with a 
polyclonal anti-FLT3 antibody. B. The expression and phosphorylation of STAT5 in Ba/F3 
MIY, FLT3-ITD and FLT3-D835H expressing cells treated with 0.1, 1 and 10µM of 
SU5614 or untreated cells was determined by Western blot analysis.  
 
These results confirm at a molecular level the different sensitivity of FLT3-TKD 
mutants to FLT3 PTK inhibitors.  
 
 
6.5 Mechanisms of drug resistance to SU5614 
6.5.1 Generation of SU5614-resistant Ba/F3 FLT3-ITD cells 
FLT3 PTK inhibitors are now being evaluated in clinical phase I/II studies in 
patients with AML (see above), but it is unknown to what extent clinical resistance 
will develop and influence the clinical efficiency of these inhibitors. 
 
 
Figure 20: Generation of SU5614-resistent cell lines.  
A. The polyclonal Ba/F3 FLT3-ITD cell line was cultivated in RPMI-1640 medium 
containing 10% FBS in the presence of increasing concentrations of SU5614 B. The 
Ba/F3 FLT3-ITD-R4 cells were seeded at a density of 4x104 cells/ml in the absence and 
presence of different concentrations of SU5614 and viable cells were counted after 72 
hours by trypan blue exclusion. 
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To address this important issue, FLT3-ITD-W51 expressing polyclonal Ba/F3 cells 
were cultivated either in the presence of increasing concentrations of SU5614 
(0.2µM to 0.8µM) or in the absence of inhibitor (control cells) for a time period of 3 
months (Figure 20A). After a cultivation period of 2 weeks at a concentration of 
0.2µM SU5614 two independent cell lines were obtained that were each split in 
two sublines (ITD-R1+R2 and ITD-R3+R4, respectively). In contrast to the control 
cell line all four cell lines (ITD-R1-R4) growing in the presence of inhibitor 
developed a partial resistance to SU5614 and showed an IC50, which was at least 
7-fold higher than the IC50 of control Ba/F3 FLT3-ITD cells (Table 5).  
 
A representative example is shown in Figure 20B: Ba/F3 FLT3-ITD-R4 cells were 
cultured for 72 hours in the presence of increasing concentration of SU5614. The 
IC50 for SU5614 was 0.2µM in the control ITD cell line and 1.3 µM in ITD-R4 cells. 
At high concentrations of 10µM of inhibitor the ITD-R4 line was still sensitive to the 
growth inhibitory activity of SU5614 showing that the proliferation of these cells 
was still dependent on the presence of the activating FLT3 mutant. 
 
 
Table 5: Functional and molecular characterization of Ba/F3 FLT3-ITD-R1-4 cells. 
The IC50 of SU5614 and Ara-C in ITD-R1-4 cells was determined as described in Figure 
20. FLT3 expression was measured by FACS and the mean channel fluorescence (MCF) 
was calculated. The expression of FLT3 (WB) was determined by Western blot analysis 
using an anti-FLT3 antibody. The blot was stripped and reprobed with an anti-β-actin 
antibody. The results were quantified by densitometry according to the FLT3-ITD/β-actin 
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ratio of parental cells that was set to 100%. FLT3-TKD mutation indicates the presence 
(Y842H and D835N) (or absence (-)) of point mutations in tyrosine kinase domain (TKD). 
 
 
6.5.2 Activation of STAT5 and MAPK in FLT3-ITD-R1-4 cell lines in response 
         to SU5614 
To confirm the resistance to SU5614 at a molecular level, we analyzed two 
important downstream targets of FLT3: STAT5 and MAPK. For this purpose FLT3-
ITD-R2 and R4 cell lines were incubated with different concentrations of SU5614 
(0, 1 and 10µM) for 4 hours. As shown in Figure 21, SU5614 efficiently induces 
dephosphorylation of STAT5 and MAPK at a concentration of 1µM in Ba/F3 FLT3-
ITD cells. In contrast to the parental cell line, STAT5 and MAPK were still 
phosphorylated in the FLT3-ITD-R2 and R4 cells even in presence of 10µM 
SU5614. These results are in good agreement with the IC50 of these cell lines in 
cell proliferation assays showing a 4 fold higher IC50 of ITD-R2 compared to ITD-
R4 cells (see Table 5).  
 
- 56 -                                     
Figure 21: Activation of STAT5 and MAPK in FLT3-ITD-R1-4 cell lines in response to 
SU5614. 
The phosphorylation status of STAT5 and MAPK in extracts of Ba/F3 FLT3-ITD and FLT3-
ITD-R4/2 cells treated with 1 and 10 µM of SU5614 was determined by Western-Blot 
analysis using the polyclonal anti-pSTAT5 (A.) and anti-pMAPK antibodies (B.). 
Expression of STAT5 and MAPK in the same lysates was analyzed by immunoblotting 
with polyclonal anti-STAT5 and anti-MAPK antibodies.  
 
   
 
6.5.3 Ba/F3 FLT3-ITD-R1-4 cells are resistant to the FLT3 PTK inhibitor 
AG1295, but not to Genistein and Ara-C 
To further characterize the SU5614-resistant cell lines and analyze whether these 
cells developed a specific resistance to FLT3 PTK inhibitors, we cultivated FLT3-
ITD-R1-4 cells in the presence of two different PTK inhibitors: either AG1295, that 
has inhibitory activity to class III PTK (Levis, Tse et al. 2001) or the broad 
spectrum PTK inhibitor Genistein. (Akiyama, Ishida et al. 1987) We could 
demonstrate that all SU5614-resistant cell lines developed also resistance to the 
FLT3 selective PTK inhibitor AG1295 (Figure 22A,B), but not to Genistein (Figure 
22C).  
Further we investigated whether the ITD-R1-4 cells developed an unspecific 
resistance to apoptotic cell death induced by cytotoxic drugs. For this purpose we 
exposed these cells to different concentrations of Ara-C (cytosine arabinoside, 0-5 
µg/ml), a deoxycytidine analogue that is the most effective cytotoxic agent in the 
treatment of AML. We found that FLT3-ITD-R1-4 mutants are sensitive to Ara-C at 
a level comparable to that seen in the parental FLT3-ITD line (Figure 22B, 
summarized in Table 5). 
These data clearly show that the ITD-R1-4 cell lines are resistant to the growth 
inhibitor activity of the FLT3 PTK inhibitor AG1295, but not to unselective PTK 
inhibitors or the cytotoxic agent Ara-C. 
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Figure 22: Ba/F3 ITD-R1-4 cells are resistant to AG1295, but not to Genistein and 
Ara-C. 
A. Ba/F3 FLT3-ITD-R1-4 cells were seeded in the absence or presence of 5µM AG1295 
and counted after 48 hours by trypan blue exclusion. B. Parental Ba/F3 FLT3-ITD and 
FLT3-ITD-R4 cells were cultured for 48 hours in the absence of IL-3 with different 
concentrations of Ara-C. C. Parental Ba/F3 FLT3-ITD and FLT3-ITD-R4 cells were 
cultured for 72 hours in the absence of IL-3 with different concentrations of Genistein (as 
indicated). 
 
 
6.5.4 Expression of FLT3 protein in resistant cell lines 
Overexpression of the target kinase is a well known mechanism of PTK-inhibitor-
resistance. (le Coutre, Tassi et al. 2000; Mahon, Deininger et al. 2000; Weisberg 
and Griffin 2000)To further evaluate the mechanisms of SU5614 resistance in the 
ITD-R1-4 cell lines we analyzed FLT3 surface expression by flow cytometry using 
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a PE-labelled monoclonal anti-FLT3 antibody. All resistant cell lines expressed 
significantly higher levels of FLT3 in comparison to the parental FLT3-ITD cell line 
(Figure 23, Table 5).  
 
These data were confirmed by Western blot analyses using a polyclonal antibody 
directed against the interkinase domain of FLT3. Identical protein loading in all 
lanes was confirmed by immunoblotting using an anti-ß-actin antibody. FLT3 
expression was significantly higher in ITD-R4- (1285%), ITD-R3- (1016%), ITD-
R2- (918%) and ITD-R1-cells (725%) compared to FLT3 levels in the parental 
FLT3-ITD cell line (100%).  
 
Figure 23: Expression of FLT3 in SU5614-resistent cell lines in comparison to 
parental FLT3-ITD cells. 
A. The expression of FLT3 in Ba/F3 FLT3-ITD-R1-4 was analyzed by FACS analysis. 
Open histograms represent isotype control (PE-labelled control antibody); filled 
histograms show fluorescence intensity of CD135. B. FLT3 expression was determined by 
immunoblotting using a polyclonal anti-FLT3 antibody.  
 
 
6.5.5 The SU5614 resistant ITD-R1-4 cell lines acquired distinct FLT3-TKD 
mutations 
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Another mechanism of clinical resistance to PTK inhibitors represents the 
acquisition of distinct mutations in the ATP-binding site and the kinase activation 
loop. This phenomenon was first described in patients with CML who developed 
clinical resistance to imatinib and were found to carry imatinib-resistant point 
mutants of BCR-ABL in their leukemic blasts. (Gorre, Mohammed et al. 2001; 
Branford, Rudzki et al. 2002; Hofmann, Jones et al. 2002; Roumiantsev, Shah et 
al. 2002; Shah, Nicoll et al. 2002; von Bubnoff, Schneller et al. 2002)We 
hypothesized that similar mechanisms might also be responsible for resistance to 
FLT3 PTK-inhibitors in SU5614-resistant FLT3-ITD cell lines. For this purpose we 
analyzed the known hot spot regions for activating mutations in the FLT3 gene 
found in patients with AML: the juxtamembrane region (JM) and the activation loop 
of the kinase domain. The JM region was screened for mutations using the 
previously published primers 11F and 12R and subsequent visualization of the 
PCR-products in agarose gels. (Kiyoi, Naoe et al. 1997; Schnittger, Schoch et al. 
2001)The ITD-R1-4 lines expressed the parental ITD (W51) mutation, as shown by 
an identical size of the PCR product compared with the control cell line (Figure 
24A). 
To screen for mutations in the TKD domain we used melting curve analyses after 
amplification of a 244 base pair fragment by real-time PCR as described 
previously. (Schnittger, Schoch et al. 2001; Schnittger, Boell et al. 2002)The 
design of the hybridization probe allows detection of the point mutations and 
insertions/deletions ranging from amino acid 825 to 839 in the TKD domain of 
FLT3. The real-time PCR analysis demonstrated abnormal melting curves for the 
ITD-R3 and R4 mutants using either cDNA or genomic DNA as a template. 
Nucleotide sequencing of genomic DNA from these cells confirmed a single and 
identical G→A nucleotide (nt) exchange in both the ITD-R3 and ITD-R4 cell lines 
resulting in a D835N mutation.  Sequential analysis of the FLT3-ITD-R4 cell line at 
12 weeks and 18 weeks during selection with SU5614 indicated that the ratio of 
D835N/D835 DNA continuously increased over time (Figure 24B). The melting 
curve analyses shown in Figure 9B clearly demonstrates that the D835N mutant 
allele accounted for approximately 50% of DNA after 12 weeks of selection and 
increased to 100% of total DNA after continuous exposure to SU5614 for another 
6 weeks. These results were confirmed by direct nucleotide sequencing of the 
DNA templates used for melting curve analysis (data not shown).  
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Figure 24: Molecular characterization of SU5614-resistant cells. 
A. The juxtamembrane region of FLT3 was amplified by PCR using the published primer 
pair (11F and 12R) (Kiyoi, Naoe et al. 1997; Schnittger, Schoch et al. 2001)and 
amplification products were separated by agarose gel electrophoresis and viewed under 
UV illumination after ethidium bromide staining. M: DNA molecular weight marker, H2O: 
water control, Ba/F3: native Ba/F3 cells, WT: Ba/F3 FLT3-WT, ITD: Ba/F3 FLT3-ITD, ITD-
R1-4: Ba/F3 FLT3-ITD-R1-4, PP: positive control (AML patient carrying a FLT3-LM). B. 
Detection of FLT3-TKD mutations was performed by melting curve analysis after 
amplification of a 244 bp fragment by real time PCR as described previously. (Schnittger, 
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Schoch et al. 2001; Schnittger, Boell et al. 2002)In the presence of the FLT3-TKD wild 
type sequence or the FLT3 TKD mutant DNA the fluorescence peak is observed at 63°C 
and 55°C, respectively. C. The structural domains of the FLT3 protein with the position of 
the TKD mutations found in Ba/F3 FLT3-ITD-R1-4 cells (D835N and Y842H) are shown. 
 
After the identification of a D835N mutant in ITD-R3 and R4 cells, we sequenced 
the entire TKD domain of the ITD-R1 and R2 cell lines to screen for further 
mutations outside the region that was covered by the hybridization primers used in 
the light cycler analysis. Direct nucleotide sequencing clearly demonstrated that 
both the ITD-R1 and R2 cells carried a T→C nucleotide substitution in codon 842 
of FLT3 resulting in an Y842H mutation (Figure 24C).  
Taken together, these data clearly indicate that distinct mutations in the PTK 
domain of FLT3 are acquired in Ba/F3 FLT3-ITD cells during selection with the 
FLT3 PTK inhibitor SU5614.  
 
 
6.6 “Dual” mutants FLT3 ITD-TKD are resistant to SU5614 
 
6.6.1 The FLT3-ITD/TKD “dual” mutation is responsible for the SU5614         
resistant phenotype in FLT3-ITD-R1-4 cells 
To confirm that the D835N and Y842H TKD mutations are responsible for the 
resistance to SU5614 in ITD-R1/2 and ITD-R3/4 cells, we introduced either the 
D835N or the Y842H mutation in the FLT3-WT and the FLT3-ITD constructs.  
Then Ba/F3 cell lines expressing the FLT3-D835N, Y842H or the FLT3-ITD mutant 
alone were generated. In addition, the FLT3 “dual” mutant FLT3-ITD/D835N and 
FLT3-ITD/Y842H Ba/F3 cell lines were established. All FLT3 mutants conferred IL-
3 independent growth to Ba/F3 cell lines (data not shown, summarized in Table 6).  
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Table 6: Characterization of Ba/F3 cells expressing FLT3-ITD/TKD dual mutants. 
The IC50 of SU5614 in Ba/F3 cell lines expressing either the D835N or Y842H or the 
FLT3-ITD mutant alone and the FLT3-ITD/D835N, FLT3-ITD/Y842H “dual” mutants was 
determined as described in Figure 10.  
 
As shown in Figure 25A, the IC50 of FLT3-D835N cells to SU5614 did not 
significantly differ from the IC50 of FLT3-ITD cells (IC50 =0.1µM and 0.08µM 
respectively). In contrast, the FLT3-ITD/D835N dual mutant cells were partially 
resistant to SU5614 at levels comparable to the original ITD-R4 cell line (IC50=1.0 
and 1.3µM respectively). Similar results were obtained when FLT3-Y842H and 
FLT3-ITD/Y842H cell lines were analyzed (Figure 25B, Table 5). 
We further analyzed whether the “dual” FLT3 ITD/TKD mutant provides a 
competitive growth advantage to Ba/F3 cells in the absence or presence of 0.2µM 
of SU5614 compared to the parental ITD cell line. For this purpose, we mixed MIG 
FLT3-ITD (GFP+) and MIY FLT3-ITD/D835N (YFP+) expressing Ba/F3 cells in a 
ratio of 10:1 and measured the percentage of GFP+ and YFP+ cells every 3-4 days 
for a time period of 2 weeks by FACS analysis (Figure 26A,B). 
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Figure 25: The FLT3-ITD/D835N and the FLT3-ITD/Y842H dual mutants restore the 
SU5614-resistant phenotype in Ba/F3 cells. 
 
(A.) The Ba/F3 FLT3-ITD, FLT3-D835N and FLT3-ITD/D835N, (B.) FLT3-Y842H and 
FLT3-ITD/Y842H expressing cells were seeded at a density of 4x104 cells/ml in the 
absence and presence of different concentrations of SU5614 and viable cells were 
counted after 72 hours by trypan blue exclusion.  
 
We could show that over a time period of 14 days the FLT3-ITD/D835N “dual” 
mutant cells had a substantial competitive growth advantage in the presence, but 
not in the absence of SU5614. The percentage of FLT3-ITD-D835N-YFP positive 
cells in the presence of SU5614 increased from 10% (day 0) to 88% (day 14), 
whereas the percentage of “dual” mutant YFP positive cells cultured in the 
absence of SU5614 increased to only 22%. 
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Figure 26: The FLT3-ITD/D835N dual mutant provides a competitive growth 
advantage to Ba/F3 cells in the presence of SU5614. 
A. and B. MIG FLT3-ITD (GFP+) and MIY FLT3-ITD/D835N (YFP+) expressing Ba/F3 
cells were mixed in a ratio of 10:1 and the percentage of GFP+ and YFP+ cells was 
measured every 3-4 days for a time period of 2 weeks by FACS analysis in the presence 
(A.) or absence (B.) of 0.2µM of SU5614. 
 
These data clearly show that the FLT3-ITD/TKD dual mutant restores the ITD-R1-
4 phenotype. Therefore, the acquisition of specific TKD mutations in the FLT3-ITD 
gene represents a new mechanism of resistance to FLT3 PTK inhibitors in vitro. 
 
 
6.6.2 “Dual” mutants are resistant to SU5614 independent from kind of 
mutation in juxtamembrane region of FLT3 
We hypothesized, that various length of mutations in JM region can lead to 
differences in sensitivity to SU5614. For this purpose we generated Ba/F3 cells 
transformed with FLT3-V592A/D835N and FLT3-NPOS/D835N mutants. The 
FLT3-NPOS mutant contains a 28-amino acid duplicated sequence inserted 
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between amino acids 610/611 in contrast to FLT3-W51 mutant, which contains 
only 6-amino acid duplicated sequence inserted between amino acids 601/602 
and FLT3-V592A contains only point mutation. 
Our results clearly demonstrate, that all of these dual mutants show partially 
resistance to SU5614 although at a different degree (IC50=0.3µM for V592A-
D835N- only weak resistance and 1µM for NPOS-D835N - more strong) (Figure 
27). 
 
 
Figure 27: The FLT3-ITD/D835N and the FLT3-ITD/Y842H dual mutants restore the 
SU5614-resistant phenotype in Ba/F3 cells. 
(A.) The Ba/F3 FLT3-ITD, FLT3-D835N and FLT3-ITD/D835N, (B.) FLT3-Y842H and 
FLT3-ITD/Y842H expressing cells were seeded at a density of 4x104 cells/ml in the 
absence and presence of different concentrations of SU5614 and viable cells were 
counted after 72 hours by trypan blue exclusion.  
 
 
 
6.6.3 The presence of FLT3-ITD and FLT3-TKD mutations on the two 
‘‘alleles’’ do not confer SU5614 resistance 
 
Furthermore, we analyzed whether the ITD and TKD mutations, which occurred on 
the different alleles, also might lead to resistance to PTK-inhibitors. For this 
purpose, we generated Ba/F3 cells transformed with FLT3-ITD//FLT3-D835N and 
FLT3-ITD//FLT3-WT. As a control we generated Ba/F3 FLT3-ITD cell line. Our 
data clearly show that occurrence of ITD and TKD mutations on two alleles is not 
sufficient to induce resistance to PTK-inhibitor (Figure 28).  
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Figure 28: The FLT3-ITD//FLT3-D835N and the FLT3-ITD//FLT3-WT mutants are 
completely sensitive to SU5614. 
The Ba/F3 FLT3-ITD, FLT3-ITD//FLT3-D835N and FLT3-ITD//FLT3-WT expressing cells 
were seeded at a density of 4x104 cells/ml in the absence and presence of different 
concentrations of SU5614 and viable cells were counted after 72 hours by trypan blue 
exclusion.  
 
These data clearly confirm that occurrence of LM and TKD mutations on the same 
allele, but not on two alleles lead to resistance to the PTK-inhibitor SU 5614. 
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7. DISCUSSION 
 
 
7.1 Functional characterization of two “new’’ FLT3 mutations in 
AML: V592A and 840GS 
 
The data presented here clearly indicate that activating mutations in the FLT3 
gene do not only occur within the juxtamembrane domain and in codons D835/836 
but also in other positions of the A-loop of the catalytic domain. The A-loop 
represents a hot spot region for activating mutations in class III RTK which have 
been described for KIT (D816) and FLT3 (D835/836) (Yamamoto, Kiyoi et al. 
2001)These mutations induce a conformational change of the A-loop which results 
in the opening of the catalytic pocket and a constitutively active kinase activity. 
Although no structural data on the catalytic domain of FLT3 are available which 
would allow the detailed structure-function analysis, the close proximity to the AA 
D835/836 suggests a similar mechanism of kinase activation by the FLT3-840GS 
mutant. 
 
Activating mutations of the FLT3 gene provide an essential anti-apoptotic and pro-
proliferative signal in primary AML cells and cell lines (Hayakawa, Towatari et al. 
2000; Mizuki, Fenski et al. 2000; Tse, Mukherjee et al. 2000) Our results clearly 
indicate that the FLT3840-GS mutant is hyperphosphorylated on tyrosine residues 
and induces IL-3 independent growth in Ba/F3 cells. These in vitro data underline 
the pathophysiologic role of this mutant for the leukemic phenotype in patients with 
AML.  
 
In order to identify downstream targets of FLT3-840GS mutant receptor, we 
performed Western blot analysis with phosphospecific antibodies against STAT5 
and MAPK. Our results confirmed strong MAPK activation by the FLT3-840GS, but 
only weak STAT5 activation. We hypothesize the weak STAT5 activation 
translates into a weak transforming activity of this mutation and used IL-3 
stimulation to induce maximal proliferation activity. Our results show that IL-3 
stimulation leads to an increased growth rate of the Ba/F3 FLT3-840GS cells in 
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dose-dependent manner. Therefore, we suggest, that the FLT3-840GS mutant 
requires additional mitogenic signal for full transformation. Possible explanation of 
these results might be found in recently published article from Y.Minami et al, 
where the authors show differences between anti-apoptotic pathways of wild-type 
and mutated FLT3 receptors. The authors showed that STAT5 is the most 
important downstream target for FLT3-ITD mutants, but the MAPK pathway is 
indispensable for the FLT3-WT receptor. Based on the data shown here we 
hypothesize that the FLT3-840GS mutant uses similar pathway compared to the 
FLT3-WT receptor. 
 
Another mutation that was found and described in this work is the FLT3-V592A. 
This mutation represents the first point mutation in JM domain of FLT3. The 
mutation was found in two AML cell lines (MM6 and MM1), but the frequency in 
patients with AML is unknown. Probably the V592A represents rare mutation, but it 
represents a good model for future investigations of FLT3 signalling. Recently it 
was shown by Di Maio et al. that amino acid substitution in JM region of the 
PDGFR led to activation of the receptor. V592 of FLT3 is also a highly conserved 
amino acid in class III RTK (Rosnet, Marchetto et al. 1991)and further analysis will 
be needed to investigate the mechanism of transformation by this mutation.   
 
The data demonstrated here show that FLT3-V592A is an activating mutation, 
which leads to hyperphosphorylation of the FLT3 receptor and induces IL-3-
independent growth in Ba/F3 cells. Our data also demonstrate that the FLT3-V592 
mutant receptor activates two known downstream targets of FLT3: STAT5 and 
MAPK. Furthermore, the specific FLT3 PTK inhibitor SU5614 was able to inhibit 
IL-3-independent growth of MM6, MM1 (Spiekermann, Dirschinger et al. 2003)and 
Ba/F3 FLT3-V592A cells. 
 
In order to identify differences in FLT3-TKD and FLT3-V592A signalling, we 
generated 589/591 Y→F substitution mutants of either FLT3-D835Y or FLT3-
V592A. Our data show that the tyrosine residues 589/591 play a crucial role for 
transformation of Ba/F3 cells by the FLT3-V592A, but not by the FLT3-D835Y 
mutant. These findings are in good agreement with results from Kyioi et al., which 
found that these tyrosine residues are important for FLT3-ITD constructs (Kiyoi, 
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Towatari et al. 1998) Although further studies are required, we suggest, that the 
FLT3-V592A mutant and FLT3-ITD mutant activate similar signalling pathways.  
  
Although the FLT3-840GS and FLT3-V592A are probably rare mutations, they 
clearly show that activating mutations other than the FLT3-LM in the JM domain 
and FLT3D835/836 in the kinase domain exist in patients with AML.   
 
These findings are of significant clinical importance since activating FLT3 
mutations could represent selective and specific molecular target structures for 
therapeutical strategies using PTK inhibitors in AML (Levis, Tse et al. 2001; Tse, 
Novelli et al. 2001) 
 
 
 
7.2 FLT3 as a molecular target for selective therapeutic 
approaches in AML   
 
Our group and others have previously shown that selective FLT3 PTK inhibitors, 
like SU5614, AG1295, PKC412 or CEP701 can induce growth arrest and 
apoptosis in FLT3 transformed cell lines and in primary AML blasts (Levis, Tse et 
al. 2001; Kelly, Yu et al. 2002; Weisberg, Boulton et al. 2002; Yee, O'Farrell et al. 
2002; Spiekermann, Dirschinger et al. 2003) These promising in vitro results have 
stimulated phase I/II clinical studies evaluating the efficacy of FLT3 PTK inhibitors 
in patients with AML (Foran, Paquette et al. 2002; Smith, Levis et al. 2002; Stone, 
Klimek et al. 2002) 
 
In contrast to the well studied mechanisms of drug resistance found in patients 
with BCR-ABL-positive CML and ALL treated with the PTK inhibitor imatinib, little 
is known about primary and secondary mechanisms of resistance to FLT3 PTK 
inhibitors. In the present study we could show that certain activating point 
mutations found in the PTK domain of FLT3 in patients with AML significantly alter 
the sensitivity to the FLT3 PTK inhibitor SU5614. As a mechanism of secondary 
resistance we identified that FLT3-ITD transformed cell lines acquire distinct 
mutations in the TKD domain after prolonged cultivation in the presence of FLT3 
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PTK inhibitors. Reconstruction of these FLT3 “dual” mutants confirmed that the 
presence of a certain TKD-mutant on the genetic background of the ITD mutation 
was responsible for the FLT3-PTK inhibitor resistant phenotype. These data 
provide genetic evidence that pre-existing and acquired mutations in the TKD 
domain of FLT3 are sufficient to induce drug resistance to FLT3 PTK inhibitors.  
 
Genetically heterogeneous mutations in the TKD domain of FLT3 have been found 
in 7-8% of patients with AML and include point mutations at codon D835 and also 
insertions/deletions in codons 835/836 (Abu-Duhier, Goodeve et al. 2001; Thiede, 
Steudel et al. 2001; Yamamoto, Kiyoi et al. 2001; Thiede, Steudel et al. 2002) To 
analyze the sensitivity of these mutants to FLT3 PTK inhibitors, we generated 
Ba/F3 cell lines expressing the most frequent FLT3-TKD mutants, namely 
D835Y/V/H. All FLT3-TKD mutants confer IL-3 independent growth to Ba/F3 cells 
and activate similar signal transduction pathways (STAT5 and MAPK) compared 
to the FLT3-ITD construct. Importantly, these FLT3-TKD mutants differed 
significantly in their sensitivity to the growth inhibitory and apoptosis inducing 
activity of the FLT3 PTK inhibitor SU5614 in the following order: FLT3-ITD = FLT3-
D835 Y > V > H. 
 
AML-specific mutations in the TKD-domain of PTKs occur in conserved amino 
acids at codons 835/836 and 816 in FLT3 and KIT, respectively (Abu-Duhier, 
Goodeve et al. 2001; Yamamoto, Kiyoi et al. 2001; Ma, Zeng et al. 2002) It has 
been hypothesized that these mutations change the conformation of the activation 
loop (A-loop) thereby allowing spontaneous opening of the catalytic pocket and 
ligand-independent activation of the kinase (Blume-Jensen and Hunter 2001; 
Wybenga-Groot, Baskin et al. 2001) The conformational change in the A-loop of 
KIT by the D816V mutations is probably also responsible for the resistance of this 
mutant to the PTK inhibitor imatinib (Ma, Zeng et al. 2002; Zermati, De Sepulveda 
et al. 2003) Based on these findings, the observation of decreased SU5614-
sensitivity of certain FLT3-TKD mutants, e.g. D835H might also be attributable to 
the decreased affinity of the inhibitor for the catalytic pocket of FLT3. Recently, 
Grundler et al. have analyzed the sensitivity of mutants of FLT3 at codon 835/836 
to the FLT3 PTK inhibitors SU5614, PKC412 and AG1295. These authors found in 
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accordance with our results that distinct FLT3-TKD mutations lead to an altered 
sensitivity to PTK inhibitors (Grundler, Thiede et al. 2003) 
    
These findings have important clinical implications for studies evaluating the 
efficacy of FLT3 PTK inhibitors in patients with FLT3-TKD mutation positive AML. 
FLT3-TKD mutations can change the affinity of the kinase to inhibitors and might 
therefore result in clinical resistance. Treatment of AML patients carrying TKD 
mutations will therefore require a preclinical sensitivity analysis to select an 
appropriate inhibitor.  
 
 
  
7.3 ‘’Dual’’ mutations in the FLT3 gene as a cause of drug        
resistance to FLT3 PTK inhibitors 
 
We characterized 4 sublines of the parental FLT3-ITD transformed Ba/F3 cell line 
after selection in the presence of 0.2-0.8µM SU5614. All cell lines acquired a 
partial resistance to the FLT3 PTK inhibitor SU5614, but not to other apoptosis 
inducing agents like Ara-C, and showed an IC50 that was 10-25 fold higher 
compared to that of control cells. Importantly, the ITD-R1-4 lines were completely 
sensitive to SU5614 at high concentrations of 10µM of inhibitor showing that the 
proliferation of all cell lines was still dependent on the presence of the FLT3 
mutant. Additional experiments using the FLT3 PTK-inhibitor AG1295 clearly 
showed that the SU5614-resistant phenotype induced a complete cross-resistance 
with AG1295. 
 
The detailed molecular analysis showed that each of the ITD-R1-4 cell lines 
acquired a specific TKD mutation resulting either in a D835N or an Y842H FLT3 
mutant. In sequential analyses performed in the ITD-R4 cell line during selection 
with SU5614 the ratio of mutant/wild type DNA increased over time showing a 
substantial competitive growth advantage of the ITD-D835N dual mutant 
expressing cell population.  
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Clinical samples obtained from patients with AML usually carry either the ITD or 
the TKD mutation (Kottaridis, Gale et al. 2001; Thiede, Steudel et al. 2001; 
Schnittger, Schoch et al. 2002; Thiede, Steudel et al. 2002) However, in some 
patients both mutations can be detected and preliminary data suggest that these 
patients might have an even worse clinical prognosis compared to patients with a 
single ITD or TKD mutation (Karali, Dimitriadou et al. 2002; Moreno, Martin et al. 
2003) In a recent study of 979 patients, Thiede et al. found an additional TKD 
mutation in 17/200 (8.5%) of AML patients carrying a FLT3-LM. Further analysis 
revealed that 40% of the LM and TKD mutations occurred on the same allele 
showing that FLT3-LM/TKD “dual” mutants spontaneously arise in vivo (Thiede, 
Steudel et al. 2002)Although the “dual” FLT3 LM/TKD mutant is infrequently found 
at diagnosis in patients with AML, our in vitro data suggest that these mutants 
might develop during treatment with FLT3 PTK inhibitors.  
 
 
 
7.4 The FLT3-ITD/TKD dual mutation is responsible for the PTK       
inhibitor resistance.   
 
To prove that the acquisition of the TKD mutation is responsible for the FLT3 PTK 
inhibitor resistance in the ITD-R1-4 cells we generated Ba/F3 cells expressing 
either the FLT3-D835N/Y842H mutant alone or on the background of the ITD 
mutation. Although both TKD mutants alone induced IL-3 independent growth in 
Ba/F3 cells, these mutants were equally sensitive to SU5614 compared to the 
FLT3-ITD-construct. In contrast, when introduced on the ITD background, both the 
D835N and the Y842H mutation restored the SU5614 resistant phenotype in 
Ba/F3 cells. 
 
Although the FLT3-D835N and the Y842H mutants have transforming activity, 
these constructs alone did not mediate resistance to SU5614. The explanation for 
this phenomenon is not obvious, but one has to assume that only the combination 
of the ITD and the D835N/Y842H mutation changes the conformation of the 
catalytic domain in a way, which decreases its affinity for the FLT3 inhibitor. 
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Structural analyses of the Ephrin-receptors have shown that both the activation 
loop and the JM region directly interact with the PTK domain by the formation of 
autoinhibitory loops (Blume-Jensen and Hunter 2001; Wybenga-Groot, Baskin et 
al. 2001) To what extent the exact amino acid sequence and the site of insertion of 
the FLT3-LM will influence the resistance to a specific FLT3 PTK inhibitor is 
unknown. The high variability of FLT3-LM found in patients with AML must be 
taken into account when choosing an appropriate FLT3 PTK inhibitor, as it is likely 
that resistance or sensitivity to these compounds might also depend on the three 
dimensional structure of the JM-region.  
 
Although the FLT3-ITD/TKD dual mutant restores the SU5614 resistant phenotype 
when introduced in FLT3-ITD transformed Ba/F3 cells, we cannot completely rule 
out that other mechanisms might contribute to the phenotype of ITDR1-4 cells. 
Such mechanisms of resistance include altered metabolism of the drug, induction 
of drug efflux, e.g. by ABC transporters or overexpression of the target kinase. 
Very recently, Weisberg et al. have generated a PKC412 resistant Ba/F3 cell line, 
that was selected with increasing inhibitor concentrations and showed 
overexpression of FLT3 as a potential mechanism of drug resistance (Weisberg, 
Boulton et al. 2002) The detailed analysis of the ITD-R1-4 cell lines described here 
showed overexpression of FLT3 protein. Although, the FLT3-ITD/TKD dual mutant 
cells generated by transduction of Ba/F3 cells with the FLT3 cDNA carrying both 
mutations resembled the Ba/F3 FLT3-ITD-R1-4 phenotype the IC50 of SU5614 in 
ITD-R1-4 cells was still 2-5 times higher (see Table 5 and 6). It is possible that 
overexpression of the FLT3 found in the ITD-R1-4 cells might contribute to the 
enhanced SU5614-resistance in these cells compared to the “dual” ITD/TKD 
mutant Ba/F3 cells. As shown in patients with CML developing clinical resistance 
during imatinib treatment several mechanisms of resistance can occur in parallel 
and factors, other than mutations in the gene, e.g. overexpression of the target 
kinase are likely to contribute to drug resistance in vivo (Gambacorti-Passerini, 
Barni et al. 2000; le Coutre, Tassi et al. 2000; Mahon, Deininger et al. 2000; 
Weisberg and Griffin 2000). 
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7.5 Different kind of mutations in the JM region of FLT3 induce      
FLT3 PTK inhibitor resistance in dual mutant receptors. 
 
To analyze whether different mutations in JM region of FLT3 together with different 
TKD mutations would also confer resistance to FLT3 PTK inhibitors, Ba/F3 cell 
lines transformed with different dual FLT3 mutants were generated: Ba/F3 FLT3 
W51-D835N, Ba/F3 FLT3 NPOS-D835N, Ba/F3 FLT3 V592A-D835N and Ba/F3 
FLT3 W51-D835Y. We hypothesized that a different length of mutation in JM 
domain could probably lead to different conformation changes of the receptor and 
in this way to different sensitivity to PTK inhibitor. Our data demonstrated that this 
hypothesis was only partially right. Though these mutants differ in their sensitivity 
to SU5614, all of them show partially resistance to SU5614. That means that 
different kind of mutations in the JM region are able to induce PTK inhibitor 
resistance in the FLT3 TKD background.  
 
To clarify whether the two mutations have to occur on the same or on different 
alleles to induce inhibitor resistance, we generated Ba/F3 cell lines transformed 
with FLT3-ITD and FLT3-WT constructs and FLT3-ITD and FLT3-D835N mutants. 
In agreement with our theory that ITD-TKD mutation lead to conformation 
changes, the presence of the ITD and TKD mutations in different constructs was 
insufficient to confer resistance to SU5614. 
  
Taken together, mutations in the TKD domain of FLT3 can induce primary and 
secondary resistance to FLT3 PTK inhibitors. These findings have profound 
impact for clinical studies evaluating FLT3 PTK inhibitors in patients with AML and 
should be considered when clinical resistance to these compounds occurs.  
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